嬌生 (JNJ) 2026 Q3 法說會逐字稿

內容摘要

  1. 摘要
    • Q3 2026 營收為 254 億美元,年增 6%,優於市場共識,且較 Q2 有加速成長動能
    • 上修 2026 年全年營收與 EPS 指引:營收成長區間調升至 6.7%-7.1%,EPS 升至 10.95-11.05 美元(調整後)
    • 盤後市場反應未明確揭露,但管理層強調創新藥與新產品推動成長,MedTech 部分業務短期承壓
  2. 成長動能 & 風險
    • 成長動能:
      • 創新藥(Innovative Medicine)業務強勁,Q3 銷售年增 7.9%,八大品牌雙位數成長
      • 腫瘤學(Oncology)Q3 成長約 17%,多發性骨髓瘤產品組合市佔率高,RYBREVANT、INLEXZO 等新藥快速放量
      • 免疫學(Immunology)TREMFYA 銷售年增 68%,ICOTYDE 剛上市即展現強勁動能,IMAAVY 拓展新適應症
      • 神經科學(Neuroscience)CAPLYTA、SPRAVATO 等產品高成長,帶動神經精神領域領先地位
      • MedTech 新品(如 VARIPULSE Pro、Shockwave、OTTAVA 機器人手術系統)推動未來成長,Vision 事業群持續領先
    • 風險:
      • MedTech 部分業務(特別是國際心血管與外科)短期承壓,受中國 VBP、地緣政治(中東衝突)、Abiomed 研究結果影響
      • STELARA 因生物相似藥競爭大幅下滑(-54%),部分產品面臨專利到期壓力
      • Firefly Bio 與 Sail Biomedicines 交易帶來短期 EPS 稀釋,2027 年將有更大影響
      • 訴訟(如滑石粉案)與分拆(骨科事業)相關費用影響 GAAP 盈餘
  3. 核心 KPI / 事業群
    • 全球營收:254 億美元,年增 6%
    • 創新藥(Innovative Medicine):168 億美元,年增 7.9%;美國成長 11.1%
    • 腫瘤學:DARZALEX +15.6%,CARVYKTI +35.2%,TECVAYLI +77.3%,TALVEY +42.1%,RYBREVANT+LAZCLUZE +63.5%,ERLEADA +9.4%
    • 免疫學:TREMFYA +68.2%,STELARA -54%,ICOTYDE、IMAAVY 新品推動成長
    • 神經科學:SPRAVATO +36%,CAPLYTA +66.1%
    • MedTech:86 億美元,年增 2.5%;美國成長 4.8%,國際僅 0.1%
    • 心血管 Shockwave +17.2%,VARIPULSE 全球治療 AFib 病患突破 10 萬例
    • 外科(Surgery):-1%,受中國 VBP、轉型計畫與中東影響
    • 視力(Vision):+5.1%,TECNIS PureSee/TECNIS Odyssey 植入量突破 100 萬例
    • 骨科(Orthopaedics):+3.4%,新產品推動
  4. 財務預測
    • 2026 年營收預估 1007 億美元(年增 6.9%,區間 6.7%-7.1%)
    • 2026 年調整後 EPS 指引 10.95-11.05 美元(年增約 2%)
    • 全年自由現金流預估約 210 億美元
    • 2026 年營運利潤率預期下滑 60 個基點(優於 7 月預期的 75 個基點下滑)
  5. 法人 Q&A
    • Q: 雙位數成長目標是否僅靠內部投資?MedTech 是否有併購壓力?
      A: 雙位數成長目標主要靠內部戰略投資,不假設大型併購。MedTech 目前聚焦現有產品組合優化,短期無急迫性進行大型併購。
    • Q: 2027 年營收與 EPS 成長展望?Firefly/Sail 交易對 EPS 稀釋影響?
      A: 2026 年 IPR&D 稀釋 $0.64,2027 年合計 $1.36。2027 年 EPS 成長預期將優於營收成長(調整後),細節將於 12 月說明。
    • Q: ICOTYDE 上市表現與未來潛力?患者來源結構?
      A: ICOTYDE 啟動患者超過 2 萬人,近 9,000 名醫師開立,約 60% 為系統性治療新手,20% 來自口服藥,20% 來自生物製劑。預期成為創新藥最大資產之一,未來將拓展至更多適應症。
    • Q: MedTech 國際業務壓力與改善措施?中東、VBP 影響?
      A: 國際業務主要受中國 VBP、轉型計畫與中東衝突影響,屬短期因素。美國市場表現強勁,預期 Q4 及 2027 年將改善,重點推動創新產品如 OTTAVA。
    • Q: INLEXZO 市場機會與銷售數據?SunRISe-5 擴大潛力?
      A: INLEXZO 年初至今銷售近 2 億美元,Q3 超過 9,000 萬美元。現有適應症患者約 4,000 人,未來 SunRISe-5、SunRISe-3 擴大至 1.5-5 萬人,平台潛力 50 億美元以上。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to Johnson & Johnson's third quarter 2026 earnings conference call. (Operator Instructions) This call is being recorded. If anyone has any objections, you may disconnect at this time. (Operator Instructions)

    各位早安,歡迎參加嬌生(Johnson & Johnson)2026 年第三季財報電話會議。(接線員指示)本通話將被錄音。如有任何異議,您可於此時中斷連線。(接線員指示)

  • I will now turn the conference call over to Johnson & Johnson. You may begin.

    現在我將把電話會議交給嬌生(Johnson & Johnson)。您可以開始。

  • Ryan Koors - Vice President - Investor Relations

    Ryan Koors - Vice President - Investor Relations

  • Hello, everyone. This is Ryan Koors, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the third quarter of 2026 and our financial outlook for the full year.

    各位好。我是嬌生(Johnson & Johnson)投資人關係副總裁 Ryan Koors。歡迎參加本公司對 2026 年第三季營運成果的回顧,以及對全年財務展望的說明。

  • First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected.

    首先,先說明幾項會議安排。提醒各位,今日簡報及相關附表可於嬌生(Johnson & Johnson)網站的投資人關係專區 investor.jnj.com 取得。請注意,本簡報包含前瞻性陳述,內容涉及(但不限於)公司未來營運與財務表現、市場地位及業務策略。敬請注意勿過度依賴此等前瞻性陳述;其係基於本錄音日期可得資訊,並以對未來事件之目前預期為基礎。此等陳述受若干風險與不確定性影響,可能導致公司實際結果與預測有重大差異。

  • The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.

    上述風險、不確定性及其他因素之說明,載於我們向美國證券交易委員會(SEC)提交的文件中,包括可於 investor.jnj.com 及 SEC 網站查閱的 2025 年 Form 10-K。此外,今日討論的若干產品與化合物係與策略夥伴合作開發,或自其他公司取得授權。本投影片對此等合作關係予以致謝與說明。

  • Moving to today's agenda. Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the third quarter sales and P&L results. Joe Wolk, our CFO, will then close by sharing an overview of our capital allocation priorities and updated guidance for 2026. Tom Cavanaugh, Executive Vice President, Worldwide Chairman, Innovative Medicine; John Reed, Executive Vice President, Innovative Medicine Research and Development; and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A.

    接著說明今日議程。我們的董事長兼執行長 Joaquin Duato 將討論公司營運表現與成長動能。接下來我將回顧第三季銷售與損益(P&L)結果。之後,我們的財務長(CFO)Joe Wolk 將以資本配置優先事項概覽及 2026 年最新財測指引作結。Tom Cavanaugh(執行副總裁、全球主席—創新醫藥)、John Reed(執行副總裁—創新醫藥研發)以及 Tim Schmid(執行副總裁、全球主席—醫療科技 MedTech)將出席問答環節。

  • To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes.

    為確保有足夠時間回覆各位提問,我們預期本次網路直播約為 60 分鐘。

  • With that, I will now turn the call over to Joaquin.

    接下來,我將把電話交給 Joaquin。

  • Joaquin Duato - Chairman of the Board, Chief Executive Officer

    Joaquin Duato - Chairman of the Board, Chief Executive Officer

  • Thank you, Ryan, and good morning, everyone. Our strong performance in the third quarter reinforces our confidence in 2026 as a year of accelerated growth and impact for Johnson & Johnson. In Q3, we reported operational sales growth of 6% ahead of analyst consensus and increased sequential growth compared to the second quarter. With six strategic focus areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, we are leading in areas of high unmet need where innovation can make the greatest difference for patients.

    謝謝你,Ryan,各位早安。我們第三季的強勁表現,進一步強化我們對 2026 年將成為嬌生(Johnson & Johnson)加速成長並擴大影響力之年度的信心。第三季(Q3)我們公布的營運銷售成長為 6%,高於分析師共識,且相較第二季呈現更高的季增成長。我們聚焦六大策略領域:腫瘤、免疫、神經科學、心血管、外科與視力;在這些高度未被滿足需求的領域中,我們居於領先地位,創新能為病患帶來最大的改變。

  • Our powerful combination of innovative medicine and MedTech expertise strengthens our competitiveness. 29 of our products and platforms now generate at least $1 billion in annual sales. Our marketed portfolio continues to perform. Our launches are gaining significant traction, and we are advancing our new product pipeline that will sustain our growth into the next decade. With sales in the quarter of more than $25 billion, we are on track to meet our guidance and exceed $100 billion in annual revenue for the first time in our company's 140-year history.

    我們將創新醫藥與醫療科技(MedTech)專業相結合的強大組合,提升了競爭力。目前我們有 29 項產品與平台的年銷售額已達至少 10 億美元。我們已上市的產品組合持續表現亮眼。新產品上市進展迅速並獲得顯著動能,同時我們也在推進新產品研發管線,以支撐未來十年的成長。本季銷售額超過 250 億美元,我們正按計畫達成財測指引,並將在公司 140 年歷史上首次使年營收突破 1,000 億美元。

  • As we advance our differentiated portfolio and pipeline, we have a clear path to double-digit growth by the end of the decade. In Innovative Medicine, we delivered operational sales growth of 7.9% with eight brands growing double-digits.

    隨著我們推進具差異化的產品組合與研發管線,我們已具備在本十年末達成雙位數成長的清晰路徑。在創新醫藥(Innovative Medicine)方面,我們實現 7.9% 的營運銷售成長,且有八個品牌達成雙位數成長。

  • Let's start with Oncology. We are making progress to redefine cancer care from treatment to cure. In the third quarter, our Oncology business grew approximately 17%. Our multiple myeloma portfolio and pipeline are unmatched, with 80% of patients receiving a Johnson & Johnson therapy as part of their treatment journey. And we continue to strengthen the body of evidence supporting our recently launched multiple myeloma therapies and combination regimens.

    先從腫瘤領域談起。我們正推動進展,致力於將癌症照護從「治療」重新定義為「治癒」。第三季,我們的腫瘤業務成長約 17%。我們在多發性骨髓瘤的產品組合與研發管線無可匹敵,約 80% 的病患在其治療歷程中會使用嬌生(Johnson & Johnson)的療法。我們也持續強化證據基礎,以支持近期上市的多發性骨髓瘤療法與合併治療方案。

  • New Phase 3 results announced in July demonstrated that the combination of TECVAYLI plus TALVEY reduced the risk of disease progression or death by 89% as early as the second line of treatment. In solid tumors, sales of RYBREVANT increased by 64%, reflecting its strength in lung cancer. And by the end of the year, we expect to receive US FDA approval for RYBREVANT FASPRO in advanced head and neck cancer, a disease with significant unmet needs.

    7 月公布的最新第三期(Phase 3)結果顯示,TECVAYLI 加上 TALVEY 的合併療法,最早在第二線治療即能將疾病惡化或死亡風險降低 89%。在實體腫瘤方面,RYBREVANT 銷售成長 64%,反映其在肺癌領域的強勁表現。此外,我們預期在今年底前取得美國 FDA 對 RYBREVANT FASPRO 用於晚期頭頸癌的核准;該疾病仍存在顯著未被滿足的醫療需求。

  • In bladder cancer, INLEXZO has rapidly emerged as a market leader for new patient share, just one year after its launch. Nearly one in three eligible patients started on an INLEXZO regimen in the third quarter, demonstrating its growing role in transforming care in high-risk non-muscle invasive disease.

    在膀胱癌方面,INLEXZO 於上市僅一年後,即迅速成為新病患市占的市場領導者。第三季,近三分之一符合條件的病患以 INLEXZO 方案起始治療,顯示其在改變高風險非肌層浸潤性疾病照護方面的角色日益重要。

  • During the quarter, we also invested to bolster our Oncology pipeline. We completed our acquisition of Firefly Bio, adding a promising new degrader antibody conjugate platform that targets drivers of difficult to treat cancers, including KRAS. Our ambition is to become the number one oncology company by 2030, with sales projected to exceed $50 billion.

    本季我們也加大投資以強化腫瘤研發管線。我們完成對 Firefly Bio 的收購,新增一個具前景的新型降解劑抗體偶聯(degrader antibody conjugate)平台,可鎖定難以治療癌症的驅動因子,包括 KRAS。我們的目標是在 2030 年成為腫瘤領域第一名的公司,預期銷售額將超過 500 億美元。

  • Turning to Immunology. We are building on our 25-year legacy to drive industry-leading innovation for patients. TREMFYA delivered exceptional sales growth of 68% in the quarter, reflecting strong momentum across its indications. In the US, it is now the number one IL-23 inhibitor in new-to-brand share in Crohn's disease, ulcerative colitis, and psoriatic arthritis. And we continue to generate evidence that reinforces TREMFYA'S clinical differentiation.

    接著談免疫領域。我們在 25 年的傳承基礎上持續深耕,為病患推動業界領先的創新。TREMFYA 本季銷售大幅成長 68%,反映其在各適應症上的強勁動能。在美國,TREMFYA 目前在克隆氏症、潰瘍性結腸炎與乾癬性關節炎的「新處方轉入品牌」(new-to-brand)市占中,已成為 IL-23 抑制劑的第一名。我們也持續產出證據,進一步強化 TREMFYA 的臨床差異化。

  • Based on the landmark STAR study, TREMFYA is the first and only IL-23 inhibitor to demonstrate positive outcomes in axial disease clinical trials, including significant improvement in spinal pain, stiffness, and inflammation in patients with psoriatic arthritis. This momentum reinforces our conviction in TREMFYA as a foundational medicine in inflammatory bowel and psoriatic diseases and our belief that it can grow into a $10 billion-plus franchise.

    基於具里程碑意義的 STAR 研究,TREMFYA 成為首個且目前唯一在軸性病變臨床試驗中證實具正向結果的 IL-23 抑制劑,包括在乾癬性關節炎患者中,脊椎疼痛、僵硬與發炎均有顯著改善。此一動能強化我們的信念:TREMFYA 將成為發炎性腸道疾病與乾癬性疾病的基礎用藥(foundational medicine),並有望成長為年銷售超過 100 億美元的旗艦產品群(franchise)。

  • ICOTYDE, our first in class targeted oral peptide for plaque psoriasis, continues to outpace the recent competitors launches. More than 20,000 patients have initiated therapy through nearly 9,000 prescribers since ICOTYDE's launch in the US. We continue to make strong progress on commercial access, with ICOTYDE now broadly covered across all national plans.

    ICOTYDE 作為同類首創(first-in-class)、針對斑塊型乾癬的口服標靶胜肽,持續在表現上超越近期競品的上市進展。自 ICOTYDE 在美國上市以來,已有超過 20,000 名病患在近 9,000 位處方醫師的協助下開始治療。我們在商業給付可近性方面持續取得重大進展,目前 ICOTYDE 已在所有全國性保險計畫中獲得廣泛給付涵蓋。

  • Also this quarter, IMAAVY was approved as the first advanced treatment specifically for warm autoimmune hemolytic anemia, a rare life-threatening disease that causes severe anemia and fatigue. This new indication builds on IMAAVY's momentum in generalized myasthenia gravis and reflects its broad potential across autoantibody diseases.

    此外在本季,IMAAVY 獲核准成為首個專為溫抗體自體免疫性溶血性貧血(warm autoimmune hemolytic anemia)設計的進階治療;該疾病為罕見且可能致命,會造成嚴重貧血與疲憊。此一新適應症延續 IMAAVY 在全身型重症肌無力(generalized myasthenia gravis)上的動能,並反映其在自體抗體相關疾病上的廣泛潛力。

  • And we continue to pursue next generation therapies. In July, we announced a collaboration with Sail Biomedicines to advance in vivo CAR-T approaches for immune mediated diseases.

    我們也持續推進下一代療法。7 月,我們宣布與 Sail Biomedicines 合作,推動體內(in vivo)CAR-T 方法用於免疫介導疾病。

  • Next, in Neuroscience, we aim to transform the future of brain health by addressing complex nervous system disorders. Today, we are the definitive leader in neuropsychiatry.

    接下來,在神經科學領域,我們的目標是透過處理複雜的神經系統疾病,改變腦部健康的未來。目前,我們是神經精神醫學領域無可爭議的領導者。

  • CAPLYTA reached $1 billion in year-to-date sales, making it our 29th billion-dollar platform. Driven by strong uptake as an adjunctive treatment for major depressive disorder, CAPLYTA is now the fastest growing oral branded therapy in this space.

    CAPLYTA 年初至今銷售額達到 10 億美元,使其成為我們第 29 個十億美元平台。在作為重度憂鬱症(MDD)輔助治療的強勁採用帶動下,CAPLYTA 現已成為此領域成長最快的口服品牌療法。

  • And last month, we presented pivotal Phase 3 data that show CAPLYTA significantly and rapidly improved symptoms of bipolar mania. SPRAVATO also delivered impressive growth of 36% this quarter, reflecting strong demand in treatment-resistant depression.

    此外,上個月我們公布了關鍵性第三期(Phase 3)數據,顯示 CAPLYTA 能顯著且迅速改善雙相情感障礙躁期症狀。SPRAVATO 本季亦實現 36% 的亮眼成長,反映治療抗藥性憂鬱症的強勁需求。

  • Now let's turn to MedTech, where we delivered Q3 operational sales growth of 2.5%. While we fell short of our expectations for the segment, our conviction in our future direction has not changed. Starting with Cardiovascular, we continue to invest in heart recovery, circulatory restoration, and heart rhythm disorders to address the leading global cause of death.

    現在讓我們轉向醫療科技(MedTech),我們第三季(Q3)營運銷售成長 2.5%。雖然該部門表現未達我們的預期,但我們對未來方向的信念並未改變。從心血管領域開始,我們持續投資於心臟復原、循環修復與心律失常,以因應全球首要死因。

  • This was another strong quarter for Shockwave, our circulatory restoration business, which grew 17%. The ongoing global launch of Shockwave C2 AERO continues to broaden the reach of our intravascular lithotripsy platforms.

    對 Shockwave(我們的循環修復業務)而言,本季再度表現強勁,成長 17%。Shockwave C2 AERO 的全球持續上市,正不斷擴大我們血管內碎石術(intravascular lithotripsy)平台的觸及範圍。

  • VARIPULSE, our pulsed field ablation platform, reached a major milestone this quarter with more than 100,000 AFib patients treated worldwide. VARIPULSE Pro, which delivers five times faster ablation speed, has been very well received in Europe, where it is driving double-digit growth. And just last week, we received approval for VARIPULSE Pro in Japan.

    VARIPULSE(我們的脈衝場消融平台)本季達成重要里程碑:全球已治療超過 100,000 名心房顫動(AFib)患者。VARIPULSE Pro 可提供快五倍的消融速度,在歐洲獲得非常良好的反響,並帶動雙位數成長。就在上週,我們也取得 VARIPULSE Pro 在日本的核准。

  • With the increasing clinical experience, we are seeing differentiated benefits from VARIPULSE. In a recent retrospective analysis, VARIPULSE demonstrated a 68% lower risk of adverse cardiac events compared to a competing pulsed field ablation platform. And in heart recovery, while physician selectivity continued to affect Abiomed performance, we remain confident in the technology and focused on supporting appropriate patient selection.

    隨著臨床經驗累積,我們看到 VARIPULSE 的差異化效益。在近期一項回溯性分析中,與競品的脈衝場消融平台相比,VARIPULSE 顯示不良心臟事件風險降低 68%。在心臟復原方面,儘管醫師選擇性持續影響 Abiomed 的表現,我們仍對該技術充滿信心,並專注於支持適當的病患篩選。

  • In Surgery, we're poised to shape the next era of care through robotics, digital innovation, and advanced instrumentation. In July, the US FDA granted the de Novo authorization for OTTAVA, the world's first table integrated soft tissue robotic system. This is one of the most significant MedTech innovations we will bring to market this decade.

    在外科領域,我們將透過機器人技術、數位創新與先進器械,蓄勢引領下一個照護時代。7 月,美國 FDA 授予 OTTAVA de Novo 許可,OTTAVA 為全球首款與手術台整合的軟組織機器人系統。這是我們在本十年將推向市場的最重要醫療科技創新之一。

  • OTTAVA's unique architecture, automated features, and next generation robotic instruments help address surgeons' needs for operating room space and better surgical workflows. Its connection to our open digital ecosystem, POLYPHONIC, turns procedure data into actionable insights for clinicians. We already signed our first commercial customer for OTTAVA, and we are progressing our development program. Our investigational device exemption trial is already underway in inguinal hernia repair with future plans for indication expansion into urology and gynecology.

    OTTAVA 的獨特架構、自動化功能與新一代機器人器械,有助於滿足外科醫師對手術室空間與更佳手術流程的需求。其與我們開放式數位生態系 POLYPHONIC 的連結,可將手術程序數據轉化為臨床人員可採取行動的洞見。我們已簽下 OTTAVA 的首位商業客戶,並正推進開發計畫。我們的研究用器材豁免(IDE)試驗已在腹股溝疝氣修補術中展開,未來計畫將適應症擴展至泌尿科與婦科。

  • Finally, in Vision, we are advancing lifelong eye health to bring better sight to more than 40 million people each year. The recent US launch of TECNIS PureSee further strengthen our portfolio of intraocular lenses. During the quarter, TECNIS PureSee and TECNIS Odyssey surpassed 1 million implants worldwide, reflecting continued surgeon adoption and our leadership in personalized vision solutions.

    最後,在視力保健(Vision)方面,我們正推動終身眼部健康,每年為超過 4,000 萬人帶來更佳視力。TECNIS PureSee 近期在美國上市,進一步強化我們的人工水晶體產品組合。本季,TECNIS PureSee 與 TECNIS Odyssey 全球植入量突破 100 萬枚,反映外科醫師持續採用,以及我們在個人化視力解決方案上的領導地位。

  • We also received CE marking for ACUVUE OASYS MAX 2-week reusable lenses, expanding our ACUVUE portfolio in Europe.

    我們也取得 ACUVUE OASYS MAX 兩週更換型可重複使用鏡片的 CE 認證,擴大我們在歐洲的 ACUVUE 產品組合。

  • Overall, this quarters strong results demonstrate the impact of the choices we have made to build a foundation for durable growth. We sharpened our portfolio to focus on innovation with the greatest potential to change lives. We proved our ability to grow through a significant loss of exclusivity. Our strategic investments in high growth areas are delivering results. And our innovation engine continues to drive breakthroughs for patients. That is why we have the confidence to say that we will finish 2026 strong and that 2027 will be an even better year for Johnson & Johnson.

    整體而言,本季強勁的成果展現了我們所做選擇的影響,這些選擇為可持續的成長奠定基礎。我們精簡產品組合,聚焦於最有潛力改變生命的創新。我們證明了即使面臨重大獨家權到期(LOE),仍具備成長能力。我們在高成長領域的策略性投資正在帶來成果。而我們的創新引擎持續為病患推動突破。因此,我們有信心表示:我們將以強勁態勢完成 2026 年,而 2027 年對嬌生(Johnson & Johnson)而言將是更好的一年。

  • I will now turn the call back over to Ryan.

    我現在把電話交回給 Ryan。

  • Ryan Koors - Vice President - Investor Relations

    Ryan Koors - Vice President - Investor Relations

  • Thank you, Joaquin. Moving to our financial results. Unless otherwise stated, the percentages quoted represent operational results and therefore exclude the impact of currency translation.

    謝謝你,Joaquin。接下來談我們的財務結果。除非另有說明,所引用的百分比均為營運結果,因此不包含匯率換算的影響。

  • Starting with Q3 2026 sales results. Worldwide sales were $25.4 billion for the quarter, increasing 6%. Growth in the US was 9.1% and 1.8% outside the US. Acquisitions and divestitures had a net negative impact on worldwide growth of 10 basis points.

    先從 2026 年第三季(Q3)銷售結果開始。本季全球銷售額為 254 億美元,成長 6%。美國成長 9.1%,美國以外成長 1.8%。併購與資產處分對全球成長的淨影響為負 10 個基點。

  • Now turning to earnings. For the quarter, net earnings were $210 million, and diluted earnings per share were $0.09 versus $2.12 a year ago. Results in the quarter were impacted by the proposed talc litigation resolution as well as expenses associated with the Firefly Bio transaction and Sail Biomedicines' collaboration amounting to approximately $7 billion.

    接著談獲利。本季淨利為 2.10 億美元,稀釋後每股盈餘為 0.09 美元,去年同期為 2.12 美元。本季結果受到擬議中的滑石粉訴訟和解方案影響,亦受到與 Firefly Bio 交易及 Sail Biomedicines 合作相關費用影響,合計約 70 億美元。

  • Adjusted net earnings for the quarter were $6.3 billion. And adjusted diluted earnings per share were $2.59, representing a decrease of 6.8% and 7.5%, respectively, compared to the third quarter of 2025. Adjusted earnings in the quarter were also impacted by expenses associated with the Firefly Bio transaction and Sail Biomedicines collaboration.

    本季調整後淨利為 63 億美元。調整後稀釋每股盈餘為 2.59 美元,與 2025 年第三季相比分別下降 6.8% 與 7.5%。本季調整後獲利亦受到與 Firefly Bio 交易及 Sail Biomedicines 合作相關費用的影響。

  • I will now comment on business sales results in the quarter, focusing on the six key areas where meaningful innovation and strong commercial execution are driving our performance and fueling long-term growth. Beginning with innovative medicine, where our financial results reflect the depth of our expertise and innovation in areas of high unmet need across Oncology, Immunology, and Neuroscience.

    我接下來將評論本季各業務的銷售表現,聚焦於六個關鍵領域;在這些領域中,具意義的創新與強勁的商業執行正推動我們的表現並為長期成長注入動能。先從創新藥物(Innovative Medicine)開始,我們的財務結果反映了我們在腫瘤、免疫與神經科學等高度未被滿足需求領域的深厚專業與創新能力。

  • Worldwide sales of $16.8 billion increased 7.9%, which underscores the continued strength of our key brands and new launches. Growth in the US was 11.1% and 3.0% outside the US. Divestitures had a negative impact of 10 basis points on worldwide growth.

    全球銷售額 168 億美元,成長 7.9%,凸顯我們核心品牌與新上市產品的持續強勁表現。美國成長 11.1%,美國以外成長 3.0%。資產處分對全球成長造成 10 個基點的負面影響。

  • In Oncology, starting with multiple myeloma, DARZALEX growth was 15.6%, primarily driven by strong share gains of five points across all lines of therapy with 10 points in the frontline setting as well as continued market growth partially offset by OUS pricing headwinds.

    在腫瘤領域,先談多發性骨髓瘤:DARZALEX 成長 15.6%,主要由各治療線別市占提升 5 個百分點所帶動,其中一線治療市占提升 10 個百分點;同時市場持續成長,但部分被美國以外(OUS)定價逆風所抵銷。

  • CARVYKTI achieved growth of 35.2%, driven by share gains across earlier lines of therapy and continued site expansion. TECVAYLI growth was 77.3%, driven by launch uptake and share gains across earlier lines of therapy following last quarter's approval in the US for TECVAYLI plus DARZALEX FASPRO with US growth greater than 100%. TALVEY growth was 42.1%, driven by share gains due to increased depth of prescribing in the community setting.

    CARVYKTI 成長 35.2%,由更早期治療線別的市占提升與持續擴增治療據點所帶動。TECVAYLI 成長 77.3%,由上市採用與更早期治療線別的市占提升所驅動;在上季 TECVAYLI 加 DARZALEX FASPRO 於美國獲批後,美國成長超過 100%。TALVEY 成長 42.1%,由於在社區醫療場域處方深度增加而帶動市占提升。

  • In lung cancer, RYBREVANT plus LAZCLUZE delivered growth of 63.5% with strong share gains in the first and second lines, driven by continued launch uptake in all regions along with rapid uptake in RYBREVANT FASPRO.

    在肺癌方面,RYBREVANT 加 LAZCLUZE 成長 63.5%,在第一線與第二線治療均有強勁市占提升;這由各地區持續的上市採用,以及 RYBREVANT FASPRO 的快速採用所帶動。

  • In prostate cancer, ERLEADA delivered growth of 9.4%, with continued share gains and market growth partially offset by unfavorable patient mix.

    在前列腺癌方面,ERLEADA 成長 9.4%,市占與市場持續成長,但部分被不利的病患組合所抵銷。

  • Within Immunology, TREMFYA delivered impressive growth of 68.2% driven by a continued momentum from the IBD launch with four points of share growth in both ulcerative colitis and Crohn's disease alongside continued market growth. STELARA declined 54%, which reflects continued competitive pressures from biosimilars and the ongoing shift towards novel classes. Growth in other immunology is driven by IMAAVY and ICOTYDE launch uptake in the US.

    在免疫領域,TREMFYA 交出 68.2% 的亮眼成長,主要由 IBD 上市後的持續動能所帶動;在潰瘍性結腸炎與克隆氏症兩者中,市占各提升 4 個百分點,同時市場持續成長。STELARA 下滑 54%,反映生物相似藥帶來的持續競爭壓力,以及市場持續轉向新型藥物類別。其他免疫產品的成長則由 IMAAVY 與 ICOTYDE 在美國的上市採用所驅動。

  • In Neuroscience, SPRAVATO grew 36%, driven by continued share gains reflecting strong physician adoption and increased patient demand. CAPLYTA showed significant growth of 66.1% driven by strong continued launch momentum in adjunctive major depressive disorder and continued demand increases across bipolar disorder and schizophrenia.

    在神經科學領域,SPRAVATO 成長 36%,主要受惠於持續的市占提升,反映醫師採用度強勁以及病患需求增加。CAPLYTA 顯著成長 66.1%,動能來自其在重度憂鬱症加用治療(adjunctive)適應症的持續強勁上市推進,以及在雙相情感障礙與思覺失調症領域需求持續增加。

  • Now moving to MedTech. Worldwide sales of $8.6 billion increased 2.5%, with growth of 4.8% in the US and 0.1% outside the US. Overall, Cardiovascular grew 4.1%, including 20 basis points related to acquisitions.

    接著談到醫療科技(MedTech)。全球銷售額 86 億美元,成長 2.5%,其中美國成長 4.8%,美國以外成長 0.1%。整體而言,心血管業務成長 4.1%,其中包含與併購相關的 20 個基點貢獻。

  • Electrophysiology delivered growth of 4.4% driven by procedure expansion, commercial execution, and new product performance, partially offset by competitive PFA pressures, which were more pronounced in ASPAC this quarter, as well as the lapping of prior year OUS inventory dynamics.

    電生理業務成長 4.4%,主要由手術量擴張、商業執行力以及新產品表現所帶動;但部分被競爭性 PFA 壓力所抵銷,本季在亞太地區(ASPAC)更為明顯,此外亦受到去年美國以外(OUS)庫存動態基期效應影響。

  • Abiomed saw a decline of 1.5% due to lower patient volume. There are encouraging signals in the US performance with improvement in the quarter supported by acute myocardial infarction, cardiogenic shock, and Impella 5.5 continuing to gain adoption.

    Abiomed 因病患量較低而下滑 1.5%。美國市場表現出現令人鼓舞的訊號,本季在急性心肌梗塞、心因性休克,以及 Impella 5.5 持續提升採用度的支持下有所改善。

  • Shockwave grew double-digits at 17.2% driven by continued adoption of coronary and peripheral products as well as new product launches and the reimbursement in the office based lab setting within the US. Surgery saw a decline of 1%, including a negative impact of approximately 30 basis points from divestitures. The decline is more notably driven by ongoing expansion of VBP in China, surgery transformation program outcomes across the portfolio, and Middle East disruption, which impacted tender timing and ordering patterns.

    Shockwave 成長 17.2%,呈雙位數增長,主要由冠狀動脈與周邊血管產品持續被採用、新產品上市,以及在美國門診式實驗室(office-based lab)場域取得給付所帶動。外科業務下滑 1%,其中包含因資產剝離帶來約 30 個基點的負面影響。下滑更主要的驅動因素包括:中國 VBP(帶量採購)持續擴大、外科轉型計畫在整體產品組合上的成果,以及中東地區的干擾,影響標案時點與訂購模式。

  • The decline was partially offset by portfolio strength driven by recent innovations such as ETHICON 4000 and DUALTO, as well as commercial execution in biosurgery.

    上述下滑部分被產品組合優勢所抵銷,動能來自近期創新產品如 ETHICON 4000 與 DUALTO,以及在生物外科(biosurgery)領域的商業執行。

  • In Vision, growth was 5.1%, driven by premium innovation, strong execution, and global reach. Contact lenses and other products grew 4.3%, driven by strong performance in the ACUVUE OASYS 1-Day family of products, further solidifying our leadership position, partially offset by US inventory dynamics.

    在視力保健(Vision)方面,成長 5.1%,由高端創新、強勁執行力與全球覆蓋所帶動。隱形眼鏡及其他產品成長 4.3%,主要受惠於 ACUVUE OASYS 1-Day 產品家族的強勁表現,進一步鞏固我們的領導地位;但部分被美國庫存動態所抵銷。

  • Surgical Vision delivered growth of 7.1%, driven by new product innovations, robust demand for premium IOLs and strong commercial execution, partially offset by market-specific factors such as disruptions in the Middle East.

    手術視力保健(Surgical Vision)成長 7.1%,由新產品創新、對高端人工水晶體(IOL)的強勁需求以及優異的商業執行所帶動;但部分被特定市場因素所抵銷,例如中東地區的干擾。

  • Orthopaedics growth for the quarter was 3.4%, primarily driven by new product launches such as VOLT in Trauma and EMPHASYS in Hips, including strong commercial execution and VELYS pull-through in Knees.

    骨科本季成長 3.4%,主要由新產品上市帶動,例如創傷領域的 VOLT 與髖關節領域的 EMPHASYS,並包含強勁的商業執行,以及 VELYS 在膝關節業務的帶動效應(pull-through)。

  • Now turning to our consolidated statement of earnings for the third quarter of 2026. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of goods sold deleveraged by 150 basis points, driven by unfavorable product sales mix and increased intangible asset amortization expense in the Innovative Medicine segment for Intra-Cellular, partially offset by the impact of tariff recoveries in the MedTech business.

    接著看 2026 年第三季的合併損益表。我想強調幾個相較去年同期有所變動的重點項目。銷貨成本槓桿下滑 150 個基點,主要受不利的產品銷售組合,以及創新醫藥(Innovative Medicine)事業部中 Intra-Cellular 的無形資產攤銷費用增加所影響;但部分被醫療科技(MedTech)業務關稅回收(tariff recoveries)的影響所抵銷。

  • Selling, marketing, and administrative expenses were flat as a percent of sales, reflecting consistent commercial investments in the Innovative Medicine business. We continue to invest strategically in research and development, deploying approximately $4.7 billion or 18.3% of sales, which includes $1 billion related to the acquisition of Firefly Bio.

    銷售、行銷與管理費用占銷售額比重持平,反映我們在創新醫藥業務持續一致的商業投資。我們持續策略性投資研發,投入約 47 億美元(占銷售額 18.3%),其中包含與收購 Firefly Bio 相關的 10 億美元。

  • In-process research and development impairment costs of $339 million in the quarter is related to the write off of preCARDIA, a non-core asset acquired as part of the broader Abiomed transaction. Other income and expense was a net expense of $5.8 billion as compared to $478 million of income in the third quarter of 2025, with the change primarily driven by the proposed talc litigation resolution and Orthopaedics separation-related costs.

    本季在研發中(in-process)研發減損費用 3.39 億美元,係與沖銷 preCARDIA 有關;該資產為非核心資產,係作為更大範圍 Abiomed 交易的一部分所取得。其他收益與費用為淨費用 58 億美元,相較於 2025 年第三季為 4.78 億美元收益;變動主要由擬議的滑石粉(talc)訴訟和解方案,以及骨科分拆相關成本所驅動。

  • The tax rate was a small net benefit in the quarter, primarily related to the positive tax effect associated with the accrual for the proposed talc litigation resolution. More information can be found in our upcoming 10-Q for changes in taxes.

    本季稅率呈現小幅淨利益,主要與就擬議的滑石粉訴訟和解方案所提列應計項目帶來的正向稅務影響有關。關於稅務變動的更多資訊,將載於我們即將發布的 10-Q。

  • Lastly, I'll direct your attention to the boxed section of the slide, where we have also provided our income before tax, net earnings, and earnings per share adjusted to exclude the impact of intangible amortization expense and special items.

    最後,請各位留意投影片中框選的區塊;我們亦提供了剔除無形資產攤銷費用與特殊項目影響後調整的稅前利益、淨利與每股盈餘。

  • Now let's look at the adjusted income before tax by segment for the quarter. Innovative Medicine margin declined from 44.3% to 35.4%, primarily due to acquired in-process research and development expense of approximately $1 billion related to the acquisition of Firefly Bio, transaction costs for Sail Biomedicines, and unfavorable product sales mix in cost of products sold. MedTech margin increased from 21% to 22.9%, driven by the impact of tariff recoveries, partially offset by increased strategic investments in commercial capabilities. As a result, adjusted income before tax for the enterprise as a percentage of sales decreased from 35.2% to 30.2%.

    接著看本季按事業部別的調整後稅前利益。創新醫藥的利潤率由 44.3% 降至 35.4%,主要因與收購 Firefly Bio 相關、約 10 億美元的取得之在研發中研發費用,Sail Biomedicines 的交易成本,以及銷貨成本中不利的產品銷售組合。醫療科技利潤率由 21% 升至 22.9%,主要受關稅回收影響所帶動,但部分被在商業能力方面增加的策略性投資所抵銷。因此,企業層級調整後稅前利益占銷售額比重由 35.2% 降至 30.2%。

  • This concludes the sales and earnings portion of the call. And I will now turn the call over to Joe.

    以上為本次電話會議的銷售與獲利部分。接下來我把電話交給 Joe。

  • Joseph Wolk - Chief Financial Officer, Executive Vice President

    Joseph Wolk - Chief Financial Officer, Executive Vice President

  • Thanks, Ryan. Hello, everyone, and thank you for joining us today. As you heard from Joaquin and Ryan, our third quarter results were driven by the strength of our Innovative Medicine business. This performance more than offset headwinds in certain areas of MedTech, enabling us to exceed expectations on both the top and bottom line while continuing to invest in our pipeline and future growth.

    謝謝你,Ryan。各位好,感謝今天加入我們。如同各位從 Joaquin 與 Ryan 所聽到的,我們第三季的結果主要由創新醫藥業務的強勁表現所帶動。這樣的表現不僅抵銷了醫療科技某些領域的逆風,也使我們在持續投資產品線(pipeline)與未來成長的同時,於營收與獲利兩端皆優於預期。

  • We are clear on where MedTech performance needs to improve, specifically Cardiovascular and Surgery outside the US and are taking action to strengthen results. While disappointing, the underlying fundamentals of the MedTech business remain strong, supporting our confidence in the long-term for that business.

    我們清楚醫療科技的表現需要改善之處,特別是心血管以及美國以外的外科業務,並正採取行動以強化成果。雖然令人失望,但醫療科技業務的基本面仍然強勁,支持我們對該業務長期發展的信心。

  • Across Johnson & Johnson, the drivers underpinning our outlook remain firmly in place. As a result, we are raising our guidance for 2026 versus our most recent update in July. The depth of our portfolio, momentum from new product launches, and upcoming pipeline catalysts further reinforce our conviction in achieving double-digit growth by the end of this decade with sustainable growth beyond.

    在整個嬌生(Johnson & Johnson)集團,支撐我們展望的驅動因素仍然穩固到位。因此,相較於我們 7 月最近一次更新,我們上調 2026 年指引。我們產品組合的深度、新產品上市帶來的動能,以及即將到來的產品線催化劑,進一步強化我們的信念:在本十年末達成雙位數成長,並在其後維持可持續的成長。

  • Turning to financial metrics and our cash position. We ended the third quarter with approximately $17 billion of cash and marketable securities and approximately $45 billion of debt for a net debt position of approximately $28 billion, generating more than $6 billion in free cash flow in the third quarter. We remain confident in our full year free cash flow guidance of approximately $21 billion.

    接著談財務指標與現金部位。第三季末,我們持有約 170 億美元的現金與有價證券,以及約 450 億美元的負債,淨負債約 280 億美元;第三季產生超過 60 億美元的自由現金流。我們仍對全年自由現金流指引約 210 億美元充滿信心。

  • During the quarter, we completed the $1 billion acquisition of Firefly Bio, deepening capabilities in oncology with next-generation antibody engineering to address complex tumor biology. As Joaquin referenced earlier, we also entered into a collaboration with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases.

    本季我們完成以 10 億美元收購 Firefly Bio,透過次世代抗體工程深化腫瘤學能力,以因應複雜的腫瘤生物學。如 Joaquin 先前提到的,我們也與 Sail Biomedicines 達成合作,以推進用於免疫介導疾病的體內(in vivo)CAR-T 療法。

  • Our disciplined approach to capital allocation is principled on prioritizing investments that support key commercial launches, accelerating future innovation, increasing our annual dividend, and strengthening our pipeline through strategic value creating inorganic opportunities.

    我們在資本配置上的紀律性做法,係以優先投入支持關鍵商業上市、加速未來創新、提高年度股利,以及透過策略性、能創造價值的外部機會來強化產品線為原則。

  • In July, we announced an agreement for a resolution of the ovarian talc litigation for $5.5 billion, which is reflected in our third quarter GAAP results. The agreement is conditioned upon the express participation of at least 95% of the remaining ovarian claims. We are trending to meet the 95% threshold.

    7 月,我們宣布就卵巢滑石粉訴訟達成 55 億美元的和解協議,並已反映於我們第三季 GAAP 財報結果中。該協議以至少 95% 的剩餘卵巢相關索賠明確參與為前提條件。目前趨勢顯示我們可望達到 95% 的門檻。

  • Let me now turn to full year 2026 guidance. As always, our outlook reflects what we know today regarding foreign exchange rates, the broader macroeconomic environment, and other external factors. Based on our year-to-date performance and expectations for the fourth quarter, we are raising the midpoint and tightening the range of our operational sales guidance.

    接下來談 2026 年全年指引。一如既往,我們的展望反映我們目前所掌握的外匯匯率、更廣泛的總體經濟環境,以及其他外部因素。基於年初至今的表現與對第四季的預期,我們上調營運銷售指引的中位數,並收斂指引區間。

  • We now expect full year operational sales growth in the range of 6.7% to 7.1%, which represents operational sales of $100.7 billion at the midpoint or growth of 6.9%. We do not speculate on future currency movements. As of last week, the euro spot rate to the US dollar was $1.12. However, the average rate for the fiscal year stands at $1.15.

    我們目前預期全年營運銷售成長落在 6.7% 至 7.1% 的區間,中點代表營運銷售額為 1,007 億美元,或成長 6.9%。我們不對未來匯率走勢進行臆測。截至上週,歐元兌美元即期匯率為 1.12 美元。然而,本會計年度的平均匯率為 1.15 美元。

  • Based on that average rate, we estimate reported sales growth of 7.2% to 7.6% with a midpoint of $101.2 billion or 7.4%. Assuming the current spot rate holds into next year, you could expect currency to be a headwind.

    基於該平均匯率,我們估計報告口徑的銷售成長為 7.2% 至 7.6%,中點為 1,012 億美元或 7.4%。假設目前的即期匯率延續到明年,您可以預期匯率將成為不利因素。

  • Turning now to other items of the P&L. Regarding operating margin, we now expect a decline of approximately 60 basis points. This is an improvement from the 75 basis points decline reflected in our updated July guidance that included the impact of the Firefly Bio and Sail Biomedicines' transactions, which had an unfavorable impact of 150 basis points. Absent those deals, we continue to deliver base margin improvement.

    接下來談損益表的其他項目。就營業利益率而言,我們目前預期約下降 60 個基點。相較於我們 7 月更新指引中所反映的 75 個基點降幅,這是一項改善;該 7 月指引包含 Firefly Bio 與 Sail Biomedicines 交易的影響,對營業利益率造成 150 個基點的不利影響。若不計入這些交易,我們仍持續實現基礎利益率改善。

  • As a reminder, our pretax adjusted operating margin outlook also reflects the costs associated with the 53rd week of operations and our previously announced agreement with the US government to improve access to medicines.

    提醒一下,我們稅前調整後營業利益率展望亦反映了第 53 週營運所相關的成本,以及我們先前宣布與美國政府達成、用以改善藥品可近性的協議所產生的成本。

  • For net interest expense, we are lowering our guidance to $150 million to $200 million. We are also tightening the range of our effective tax rate guidance. Based on our year-to-date results, we now expect a full year effective tax rate of 17.0% to 17.5%. Given those updates, we now expect adjusted operational earnings per share in the range of $10.95 to $11.05 or 2% at the midpoint. We expect reported adjusted earnings per share of $11.05 to $11.15 with a midpoint of $11.10 or growth of 2.9%.

    就淨利息費用而言,我們將指引下調至 1.5 億至 2 億美元。我們也收斂有效稅率指引區間。基於年初至今的結果,我們目前預期全年有效稅率為 17.0% 至 17.5%。在上述更新之下,我們目前預期調整後營運每股盈餘介於 10.95 至 11.05 美元之間,中點為 2% 的成長。我們預期報告口徑的調整後每股盈餘為 11.05 至 11.15 美元,中點為 11.10 美元或成長 2.9%。

  • Excluding the impact of Firefly Bio and Sail Biomedicines' transactions of $0.64, reported EPS growth would approach 9%. As a reminder for your 2027 modeling, we expect Firefly Bio and Sail Biomedicines to have a combined dilutive impact of $1.36 per share on a full year adjusted earnings per share next year. We will provide more details on our 2027 outlook later this year at our Enterprise Business Review.

    若排除 Firefly Bio 與 Sail Biomedicines 交易帶來的 0.64 美元影響,報告口徑 EPS 成長將接近 9%。提醒各位在進行 2027 年模型推估時,我們預期 Firefly Bio 與 Sail Biomedicines 合計將在明年全年調整後每股盈餘上造成每股 1.36 美元的稀釋影響。我們將於今年稍晚在企業業務回顧(Enterprise Business Review)中提供更多 2027 年展望細節。

  • Let me now highlight several upcoming developments that reinforce our growth outlook and performance for the remainder of the year. In Oncology, we expect several important data readouts in the fourth quarter. These include data for pasritamig, a first-in-class bispecific antibody in patients with advanced prostate cancer who have progressed after multiple lines of therapy.

    接下來我想重點說明幾項即將到來的進展,這些進展將強化我們對今年剩餘期間的成長展望與表現。在腫瘤領域,我們預期第四季將有數項重要數據讀出。其中包括 pasritamig 的數據;這是一款同類首創(first-in-class)的雙特異性抗體,適用於多線治療後仍進展的晚期前列腺癌患者。

  • We also expect data for JNJ-6143, an investigational first-in-class once-daily oral therapy for metastatic castration-resistant prostate cancer. We continue to see strong adoption for INLEXZO, with year-to-date sales of approximately $200 million and expect to build on that momentum with a data readout in high-risk non-muscle invasive bladder cancer later this year. We also expect US approval of RYBREVANT FASPRO in advanced head and neck cancer.

    我們也預期將取得 JNJ-6143 的數據;這是一項研究中、同類首創、每日一次口服療法,用於轉移性去勢抗性前列腺癌。我們持續看到 INLEXZO 的採用表現強勁,年初至今銷售約 2 億美元,並預期在今年稍晚針對高風險非肌層浸潤性膀胱癌的數據讀出後,進一步延續這股動能。我們也預期 RYBREVANT FASPRO 將在美國獲准用於晚期頭頸癌。

  • In Immunology, as Joaquin referenced earlier, ICOTYDE is off to a strong start and we look forward to presenting data in psoriatic arthritis later this year. In MedTech, we expect US approval of VARIPULSE Pro in the fourth quarter, further complementing last week's approval in Japan.

    在免疫學領域,如 Joaquin 先前提到的,ICOTYDE 開局強勁,我們期待在今年稍晚公布其在乾癬性關節炎的數據。在醫療科技(MedTech)方面,我們預期 VARIPULSE Pro 將於第四季在美國獲准,進一步呼應並補強上週在日本取得的核准。

  • In heart recovery, we are taking corrective action to improve Abiomed's performance. We continue to invest in clinical evidence and expect results from the HRPCI PROTECT IV trial in 2027. The trial will have 1,252 patients, four times more than the CHIP-BCIS3 study. This large-scale study will evaluate the safety and efficacy of Abiomed's Impella CP pump during high-risk percutaneous coronary intervention.

    在心臟復原(heart recovery)方面,我們正採取矯正措施以改善 Abiomed 的表現。我們持續投入臨床證據建置,並預期在 2027 年取得 HRPCI PROTECT IV 試驗結果。該試驗將納入 1,252 名患者,是 CHIP-BCIS3 研究的四倍。這項大規模研究將評估 Abiomed 的 Impella CP 幫浦在高風險經皮冠狀動脈介入治療期間的安全性與有效性。

  • In Surgery, we are focused on commercializing OTTAVA following its recent FDA De Novo authorization. We expect adoption and revenue contribution to build over time, with the goal of establishing OTTAVA as a significant pillar of our surgery portfolio by the end of the decade.

    在外科領域,我們聚焦於在近期取得 FDA De Novo 授權後,推動 OTTAVA 的商業化。我們預期採用率與營收貢獻將隨時間逐步提升,目標是在本十年末之前,將 OTTAVA 建立為我們外科產品組合的重要支柱。

  • Regarding Orthopaedics, we remain on track for the planned separation of the DePuy Synthes by mid-2027. I'm really proud of the team working to evaluate all separation vehicles and all options are better positioned today than when we announced our intentions with this business. Given the way DePuy Synthes is performing and the momentum Namal Nawana and his team are generally generating, we are leaning towards a spin as being the best option to create long-term value for Johnson & Johnson shareholders.

    關於骨科業務,我們仍按計畫推進,預計於 2027 年年中前完成 DePuy Synthes 的分拆。我為團隊感到非常自豪,他們正致力於評估所有分拆工具與各種選項;相較於我們宣布此業務意向之時,今天各選項的條件都更為有利。鑑於 DePuy Synthes 的表現以及 Namal Nawana 與其團隊整體所帶動的動能,我們傾向認為以分拆(spin)作為最佳選項,能為嬌生股東創造長期價值。

  • That has always been our base plan, and we are confident that it can be successfully executed. We will provide additional updates as appropriate and when there is more information to share.

    這一直是我們的基本計畫,我們有信心能成功執行。我們將在適當時機、以及有更多資訊可分享時,提供進一步更新。

  • Finally, I am really looking forward to and hope you join us for the Enterprise Business Review on December 8. At that event, we will provide additional perspective on our 2027 outlook and the key drivers that reinforce our conviction in achieving double-digit growth by the end of the decade. Perhaps more importantly, we will highlight our earlier stage pipeline and how it represents the next wave of growth into the next decade.

    最後,我非常期待 12 月 8 日的企業業務回顧(Enterprise Business Review),也希望各位能一同參與。在該活動中,我們將就 2027 年展望提供更多觀點,以及強化我們對於在本十年末實現雙位數成長之信念的關鍵驅動因素。或許更重要的是,我們將重點介紹較早期的研發管線,以及其如何代表下一個十年的下一波成長。

  • Attendees will also have the opportunity to experience first hand some of our latest innovations such as OTTAVA. 2026 is on track for another successful year, exceeding expectations set at the beginning of the year. We look forward to closing out 2026 strong and setting up 2027 for continued success. Thank you to our colleagues whose dedication and commitment continue to advance innovation, improve patient outcomes and create long-term value for shareholders.

    與會者也將有機會親身體驗我們最新的一些創新,例如 OTTAVA。2026 年正朝著再度成功的一年邁進,表現超越年初所設定的預期。我們期待以強勁表現為 2026 年畫下句點,並為 2027 年的持續成功奠定基礎。感謝我們的同仁,你們的投入與承諾持續推動創新、改善病患治療結果,並為股東創造長期價值。

  • With that, we are ready to answer your questions. Kevin, can you please open the call for Q&A?

    接下來,我們準備回答各位的提問。Kevin,請你開放電話會議進入問答環節,好嗎?

  • Operator

    Operator

  • (Operator Instructions) Asad Haider, Goldman Sachs.

    (接線員指示)高盛 Asad Haider。

  • Asad Haider - Analyst

    Asad Haider - Analyst

  • Great. Thanks for taking the question, and congrats on all the progress. Just one point of clarification, on the double-digit growth by the end of the decade, the vocabulary in the press release references the progress in the underlying business quote together with strategic investments. Just want to be clear that that refers to internal investments and not M&A. That's a question we're getting this morning.

    很好。謝謝讓我提問,也恭喜各項進展。我只有一點需要釐清:關於在本十年末實現雙位數成長,新聞稿中的用語提到「基礎業務的進展」並搭配「策略性投資」。我想確認這指的是內部投資,而不是併購(M&A)。這是我們今天早上收到的問題。

  • And then Joe, on your comments that you aren't satisfied with the with MedTech performance and are taking action to strengthen that growth, is the implication there that you now feel more urgency to add to higher growth areas via M&A in MedTech? Or do you think that you have the product portfolio today to drive the improved performance you're looking for? Thank you.

    另外,Joe,針對你提到你對 MedTech 的表現並不滿意,且正在採取行動以強化成長;這是否意味著你現在覺得更有急迫性,要透過 MedTech 的併購(M&A)來增加高成長領域的布局?或者你認為目前的產品組合就足以推動你所期待的改善表現?謝謝。

  • Joseph Wolk - Chief Financial Officer, Executive Vice President

    Joseph Wolk - Chief Financial Officer, Executive Vice President

  • Yeah, Asad, thank you for your questions. On the first aspect, that is correct, your interpretation of that being internal strategic investments is what will propel us to double-digit growth by the end of this decade in the coming years with increasing performance. So that is the correct interpretation. It does not assume any inorganic additions at this moment in time, where we always are on the lookout for strategic drivers that could complement our business that makes sense to be in our hands versus where the asset would currently reside, but also creates value for the risk we're bearing on behalf of shareholders.

    是的,Asad,謝謝你的提問。就第一點而言,沒錯,你的解讀正確:推動我們在本十年末達成雙位數成長、並在未來幾年隨著表現提升而加速的,將是內部的策略性投資。所以這個解讀是正確的。目前並未假設任何外延式(inorganic)的新增;我們一向會留意能補強我們業務、且由我們持有相較於資產目前所在位置更具合理性的策略性驅動因素,同時也必須在我們代表股東承擔風險的前提下創造價值。

  • With respect to the urgency, it's an urgency to fix what we currently have. We like the portfolio and the construct that currently exists with the three focus areas of Vision Care, of Surgery, as well as Cardiovascular. I think you're very familiar, and maybe I'll even hand it over to Tim to talk about some of the things we're doing in heart recovery specifically.

    就緊迫性而言,這是一種必須修復我們目前現況的緊迫性。我們喜歡目前的投資組合與架構,聚焦於三大領域:視力保健、外科手術,以及心血管。我想你非常熟悉,也許我會把話交給 Tim,請他談談我們在心臟復原方面具體正在做的一些事情。

  • To address that, I would say is now a stable business, but we want to catalyze back to double-digit growth. We're very excited at what's on the horizon for surgery with the addition of OTTAVA over time that will be a significant contributor to growth by the end of the decade. And then as I mentioned earlier, Vision seems to be functioning well both on the surgery side as well as the contact lens side where we are the market leader.

    針對這點,我會說現在是一個穩定的業務,但我們希望催化回到雙位數成長。我們對外科手術領域的未來非常興奮,隨著 OTTAVA 隨時間加入,到了本十年末它將成為成長的重要貢獻者。另外如我先前提到的,視力保健看起來運作良好,無論是在手術端或隱形眼鏡端,我們都是市場領導者。

  • But Tim, maybe you want to offer a comment or two around Abiomed.

    不過 Tim,也許你想就 Abiomed 補充一兩點評論?

  • Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech

    Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech

  • Sure, Joe. So Asad, ultimately, Abiomed remained a temporary headwind as you saw in Q3. But our conviction in the long-term opportunity has not changed at all. The slowdown we're seeing continues to be the same issue we highlighted in thequarter before, which is this study outside of the US focused on high-risk PCI.

    當然,Joe。Asad,總體而言,正如你在第三季看到的,Abiomed 仍然是一個暫時性的逆風。但我們對長期機會的信心完全沒有改變。我們看到的放緩仍然是我們在前一季就強調的同一個問題,也就是美國以外一項聚焦高風險 PCI 的研究。

  • And importantly, we do not view these challenges as structural in nature and ones that will drive a long-term impact on the business. We're not seeing any changes in the patient need nor to reimbursement, access or any meaningful competitive pressures.

    而且很重要的是,我們不認為這些挑戰具有結構性,也不會對業務造成長期影響。我們沒有看到病患需求、給付、可近性,或任何有意義的競爭壓力出現變化。

  • We also have highlighted some questions we have around the study as to whether best practices were used in the study. And so our focus today is really on education and advancing the clinical evidence based to show the incredible impact that Impella has in both saving and improving lives.

    我們也提出了對該研究的一些疑問,例如研究中是否採用了最佳實務。因此,我們目前的重點確實在於教育與推進臨床證據基礎,以展現 Impella 在拯救生命與改善生活品質方面的驚人影響。

  • And so we believe it's a short-term headwind. It's important to recognize that in any emerging area of science always going to be debate and discussion, and our responsibility is to continue to advance the evidence base to support what's in the best interest of patients.

    因此我們認為這是短期逆風。需要認知的是,在任何新興科學領域,總會有辯論與討論;而我們的責任是持續推進證據基礎,以支持最符合病患利益的作法。

  • And in the case of Abiomed, we're doing exactly that. And so a short-term headwind, but we are very confident this is going to be a strong platform for growth for Johnson & Johnson for the for the future. Thank you.

    就 Abiomed 而言,我們正是在做這件事。所以這是短期逆風,但我們非常有信心,這將在未來成為嬌生強勁的成長平台。謝謝。

  • Operator

    Operator

  • Larry Biegelsen, Wells Fargo.

    Larry Biegelsen,富國銀行。

  • Lawrence Biegelsen - Analyst

    Lawrence Biegelsen - Analyst

  • Good morning. Thanks for taking the question. Joe, I wanted to ask about the 2027 comments you made at Deutsche Bank. On the top line, you said you expect reported sales growth to be similar to 2026 after adjusting 100 basis points for the extra week in both years, which I think would mean about 5.4% reported growth next year.

    早安。謝謝讓我提問。Joe,我想問你在德意志銀行談到的 2027 年相關評論。在營收端,你說在把兩年都因多一週而調整 100 個基點之後,你預期 2027 年的申報銷售成長會與 2026 年相近;我想這代表明年申報成長大約是 5.4%。

  • And on EPS, how should we think about your ability to grow earnings excluding IPR&D? And just remind us of how much the Firefly and Sail dilution is IPR&D this year and next year. Thank you.

    在 EPS 方面,若排除 IPR&D,我們應該如何看待你們的獲利成長能力?另外也請提醒我們,今年與明年 Firefly 與 Sail 的稀釋中,有多少是 IPR&D?謝謝。

  • Joseph Wolk - Chief Financial Officer, Executive Vice President

    Joseph Wolk - Chief Financial Officer, Executive Vice President

  • So for this year, the IPR&D dilution is $0.64. And for next year, the combination of those deals is $1.36. And the way I would think about that, Larry, and you've covered us long enough where you know that typically our income growth or EPS growth will be a little bit better than our sales growth. That's how you can think about that next year after adjusting for the $1.36 adjustment.

    今年 IPR&D 的稀釋是 0.64 美元;明年這些交易合計是 1.36 美元。Larry,你長期追蹤我們,你也知道通常我們的獲利成長或 EPS 成長會比銷售成長略好一些。因此,明年在調整 1.36 美元之後,你可以用這個方式來思考。

  • So we'll continue to look at margin improvement as part of the Orthopaedics separation, looking more holistically at our business, some of the advances we're getting with technology and getting us more efficient across all parts of our business. But that's probably a good way to kind of frame in your thinking now for 2027. But we'll be a little bit more explicit on December 8 at our Investor Day, where we'll outline specifically kind of the components to that and then even probably provide a pro forma with respect to the Orthopaedics separation should that occur at some point next year as well as a longer term outlook.

    我們也會持續把改善利潤率納入骨科分拆的一部分,更全面地檢視我們的業務,以及我們透過科技取得的一些進展,讓我們在業務各個環節都更有效率。但就目前而言,這大概是你在思考 2027 年時可以用來框架的方式。不過在 12 月 8 日的投資人日,我們會更明確地說明其中的組成要素,並且很可能也會就骨科分拆(若明年某個時間點發生)提供一份備考資訊,以及更長期的展望。

  • Operator

    Operator

  • Chris Schott, JPMorgan Chase.

    Chris Schott,摩根大通。

  • Christopher Schott - Analyst

    Christopher Schott - Analyst

  • Great. Thanks so much. Just wanted to touch base on ICOTYDE. So just two-part question here. First, can you just give us an update in terms of what you're seeing in terms of patient uptake as we think about new to biologic versus oral switches versus injectable switches?

    很好。非常感謝。我想就 ICOTYDE 追問一下,這裡有兩個問題。第一,從病患採用情況來看,你們看到的狀況如何:例如生物製劑新用戶、從口服藥轉換、以及從注射劑轉換?

  • And then bigger picture for the drug, are you talking about this as a $10 billion plus asset, but when you think about this very strong launch we've seen so far in psoriasis, we've got a number of additional indications pending. I guess how do you think about could this be a much larger asset than $10 billion as you think about the peak sales opportunity for ICOTYDE? Thanks so much.

    再從更宏觀的角度看這個藥物,你們把它描述為一個 100 億美元以上的資產;但考量到目前在乾癬上看到的非常強勁的上市表現,且還有多個額外適應症在等待核准。我想問的是,當你們思考 ICOTYDE 的峰值銷售機會時,你們如何看待它是否可能成為遠大於 100 億美元的資產?非常感謝。

  • Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

    Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

  • Great. Chris, it's Tom. Good to hear from you. First, I do want to start by recognizing Jennifer Taubert and thanking her for her tremendous leadership and partnership. Jennifer leaves Innovative Medicine incredibly well positioned as you see from our quarterly earnings with strong momentum, outstanding portfolio and pipeline, and most importantly, a great team. We're fortunate to build on that foundation she established, and I'm excited about what's ahead.

    很好。Chris,我是 Tom,很高興聽到你的聲音。首先,我確實想先肯定 Jennifer Taubert,並感謝她卓越的領導力與合作夥伴關係。從我們本季財報所呈現的強勁動能、出色的產品組合與研發管線,以及最重要的優秀團隊,你可以看到 Jennifer 讓創新醫藥(Innovative Medicine)處於非常有利的位置。我們很幸運能在她建立的基礎上繼續發展,我也對未來感到興奮。

  • And really what I'm excited about is what you're touching on right now is ICOTYDE. We do foresee ICOTYDE to be one of our biggest assets in Innovative Medicine, and it is off to an incredibly great start as you highlighted, as Joaquin highlighted on the call this morning.

    而我真正感到興奮的,正是你現在提到的 ICOTYDE。我們確實預期 ICOTYDE 會成為創新醫藥中最大的資產之一;正如你所指出的、以及今天早上電話會議中 Joaquin 所提到的,它的起步表現非常出色。

  • I think getting into some of the launch performance, you heard it from Joaquin already to date, we've seen over 20,000 patients initiated on therapy with over 8,000 prescribers or nearly 9,000 prescribers, I would say. So absolutely tracking better than some of most all launches in psoriatic diseases.

    談到一些上市表現,你已經從 Joaquin 那裡聽到,截至目前我們已看到超過 20,000 名病患開始治療,處方醫師超過 8,000 位,或我會說接近 9,000 位。因此,整體追蹤表現絕對優於乾癬性疾病領域幾乎所有的上市案例。

  • I think early prescribing trends is what you wanted to get that kind of as we think about, and we are expanding the systemic marketplace, approximately 60% of the patients are systemic naive, so they haven't received any systemic therapy. And roughly the 40% remaining: 20% are source from orals, and 20% are source from other treatments, most likely biologics as we dig into the data.

    我想你想了解的是早期處方趨勢;當我們思考並且正在擴大系統性治療市場時,大約 60% 的病患是系統性治療新手,也就是他們之前沒有接受過任何系統性治療。其餘約 40%:其中 20% 來自口服藥轉換,另外 20% 來自其他治療,隨著我們深入資料,最可能是生物製劑。

  • So I can say as you're seeing with regards to the launch performance, earlier bit of expansion of the marketplace and absolutely an opportunity to continue to drive that. Highlighted as well as Joaquin highlighted earlier, I think it's important to point out we do have broad commercial access now and preferred access in place on all national commercial plans are actively engaged to expand that to the Medicaid, Medicare population. So I would say we're very excited about the launch to date as equally as excited about the future, and we do foresee this to be one of our largest assets.

    因此我可以說,從上市表現來看,市場在早期確實有擴張,而且絕對有機會持續推動這個趨勢。另外如同 Joaquin 先前強調的,我認為也很重要的一點是:我們現在已取得廣泛的商業給付可近性,並在所有全國性商業保險計畫上建立了優先給付地位,同時也正積極推進擴展至 Medicaid、Medicare 人群。所以我會說,我們對目前的上市表現非常振奮,對未來同樣感到興奮;我們確實預期它會成為我們最大的資產之一。

  • As I pointed out, we're excited about the upcoming data readouts both with PsA Phase 3 data as well as the head-to-head STELARA data for ASCEND that we should be releasing in the coming months. And as we look to expand beyond that and we'll get into more of this at the EBR on IBD and expansions into UC and CD, expecting similar results with regards to launch performance as we go into those other indications.

    如我所指出的,我們也很期待即將公布的數據讀出,包括 PsA 的第三期數據,以及 ASCEND 與 STELARA 的頭對頭數據,我們應會在未來幾個月發布。而當我們進一步擴展時,我們也會在 IBD 的 EBR 上更深入討論,以及擴展至 UC 與 CD;我們預期在進入其他適應症時,上市表現也會呈現類似的結果。

  • Operator

    Operator

  • Joanne Wuensch, Citi.

    Joanne Wuensch,花旗。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • Good morning, and thank you for taking the question. I want to focus a little bit on MedTech here. When you use the phrase underlying fundamentals in MedTech are solid, I want to confirm that you are thinking about all the good stuff, the patient volumes, the CapEx spending from the hospitals, and then what you are seeing in terms of just general flows.

    早安,感謝讓我提問。我想在這裡稍微聚焦在醫療科技(MedTech)。當你使用「醫療科技的基本面依然穩健」這個說法時,我想確認你指的是所有正向因素:病患量、醫院的資本支出(CapEx),以及你們在整體需求流量方面所看到的情況。

  • As a sister question to that, how do you or what do you think needs to be done to improve the J&J franchise? Thank you.

    作為相關的延伸問題,你認為要改善嬌生(J&J)在這個領域的事業版圖,需要做些什麼?謝謝。

  • Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech

    Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech

  • Joanne, it's Tim. Thank you very much for the question. Let me start by really putting the overall MedTech Q3 results in context for you and all on the call. And to be clear, our performance is below the standard we have set internally and below the expectations we previously communicated to investors.

    Joanne,我是 Tim。非常感謝你的提問。我先為你以及所有與會者,把醫療科技第三季(Q3)的整體結果放在脈絡中說明。坦白說,我們的表現低於我們內部設定的標準,也低於我們先前對投資人所溝通的預期。

  • Simply put, we can do better, and we absolutely will. And right now we are focused solely on the actions needed to deliver stronger results in the fourth quarter and beyond. And that said, when -- to your question here, when we break down our results, you will see that the pressure was primarily concentrated, but actually in two very distinct areas: firstly, our performance outside of the US; and secondly, Abiomed globally, which we already touched on.

    簡單來說,我們可以做得更好,而且我們一定會做到。目前我們只專注在採取必要行動,以在第四季(Q4)及之後交出更強的成果。話雖如此,回到你的問題,當我們拆解結果時,你會看到壓力主要集中在兩個非常不同的領域:第一,我們在美國以外市場的表現;第二,全球的 Abiomed(我們剛才也已提到)。

  • And to put it in perspective, growth in the US, which as you know is the most important market, was in fact robust in the quarter and accelerated to almost 5%. Our performance outside of the US was a challenge, and it reflected a combination of mostly known headwinds which we have discussed previously. For example, in Surgery, the expected impact of the transformation program and the ongoing expansion of volume-based procurement in China. In electrophysiology, competitive intensity, especially in Asia Pacific, which is a region that you know is still relatively early in the adoption of PFA.

    從角度來看,美國的成長(如你所知是最重要的市場)在本季其實相當強勁,並加速到接近 5%。我們在美國以外市場的表現則面臨挑戰,反映了多項我們先前已討論過、且多屬已知的逆風因素的組合。例如在外科領域,轉型計畫的預期影響,以及中國持續擴大以量為基礎的集中採購。在心臟電生理方面,競爭強度上升,特別是在亞太地區;你也知道該區域在採用 PFA 上仍相對處於較早期階段。

  • We did introduce a new headwind, which is really the incremental pressure that we're seeing on the business due to the conflict in the Middle East. But when you actually step back and you look deeper into these results, we're seeing several encouraging indicators which give us confidence in a stronger Q4 and outlook beyond that.

    我們也新增了一項逆風,也就是我們因中東衝突而在業務上看到的額外壓力。但當你退一步、更深入檢視這些結果時,我們看到幾個令人鼓舞的指標,讓我們對第四季更強的表現以及之後的展望更有信心。

  • For example, in electrophysiology, in markets like Europe where we've already launched VARIPULSE Pro, which by the way is a faster and easier to use catheter, we're back to double-digit growth, and we will launch VARIPULSE Pro in Japan shortly after receiving regulatory approval last week. You can also anticipate a US launch by the end of this year.

    例如在心臟電生理方面,在像歐洲這類我們已推出 VARIPULSE Pro 的市場(順帶一提,這是一款更快、更容易使用的導管),我們已回到雙位數成長;而在上週取得監管核准後,我們也將在不久後於日本推出 VARIPULSE Pro。你也可以預期我們會在今年底前於美國上市。

  • I think in Abiomed, we've already touched on the study in high-risk PCI study where we actually believe that the methodology employed did not follow well established practices, an issue which we're addressing through education. We think we're going to get through that because the evidence base is so solid, especially in areas like AMI cardiogenic shock and we're still seeing tremendous performance of Impella 5.5. We did, by the way, already see some improvement sequentially throughout the quarter and we do believe that that business will be back to growth in short order.

    我想在 Abiomed 方面,我們已談到高風險 PCI 研究;我們認為其採用的方法學並未遵循既有且成熟的作法,這個問題我們正透過教育來處理。我們認為可以度過這段期間,因為證據基礎非常扎實,特別是在 AMI 心因性休克等領域,而且我們仍看到 Impella 5.5 的表現非常亮眼。順帶一提,我們在本季內也已看到逐季改善,我們確實相信該業務將在不久後恢復成長。

  • And now, while Q3 for MedTech was not a strong quarter, this should not distort the whole picture. As mentioned, the issues are primarily concentrated in the two areas I mentioned. It's also worth reinforcing, to your question, that the underlying procedure environment remains stable across our key markets. I know there's been a lot of debate about that. Our job now is to make sure that we convert that demand into more consistent performance.

    此外,雖然第三季對醫療科技而言不是強勁的一季,但這不應扭曲整體圖像。如前所述,問題主要集中在我提到的兩個領域。也值得再次強調,回到你的問題,我們主要市場的基礎手術/處置環境仍維持穩定。我知道外界對此有很多討論。我們現在的工作,是確保把這些需求轉化為更一致的業績表現。

  • And so we remain confident in the combination of the momentum we're seeing in the US and the moderation of these near term headwinds, which will support improved performance in Q4 while positioning us for stronger performances in 2027 and beyond. And as you've already heard from Joaquin and Joe will share more detail around what that looks like for '27 and beyond, specifically with the focus on new innovations like OTTAVA when we come together on December 8. Thank you.

    因此,我們仍對美國所展現的動能,以及這些短期逆風逐步緩和的組合充滿信心;這將支撐第四季表現改善,同時讓我們在 2027 年及之後具備更強的表現基礎。你也已聽到 Joaquin 的說明,而 Joe 會在 12 月 8 日我們聚在一起時,針對 2027 年及之後的樣貌分享更多細節,特別是聚焦於像 OTTAVA 這類新創新。謝謝。

  • Operator

    Operator

  • Jason Gerberry, Bank of America.

    Jason Gerberry,美國銀行(Bank of America)。

  • Richard Wagner - Analyst

    Richard Wagner - Analyst

  • Hello. This is Richard Wagner for Jason. I had a question regarding the ICOTYDE psoriasis launch. Are there lessons that can be learned that would be useful when ICOTYDE launches in IBD? Specifically, in IBD, competitors are developing high efficacy of combination programs and wondering how that could affect the efficacy perception by physicians of ICOTYDE. Thank you.

    你好。我是 Richard Wagner,代替 Jason 發問。我有一個關於 ICOTYDE 乾癬上市的問題。是否有可汲取的經驗教訓,能在 ICOTYDE 於 IBD(發炎性腸道疾病)上市時派上用場?具體來說,在 IBD 領域,競爭對手正在開發高療效的聯合治療方案,想請教這可能如何影響醫師對 ICOTYDE 療效的觀感?謝謝。

  • Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

    Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

  • Hi, Richard. It's Tom addressing your question. A couple things I'd point out and I'd obviously turn it over to John if he has any further remarks. So I'll say a couple things.

    嗨,Richard。我是 Tom,來回應你的問題。我先指出幾點,若 John 還有補充我也會把話題交給他。我先說幾點。

  • We absolutely know the space very well, whether to be in psoriasis or IBD. And you could tell by the launch that we had with TREMFYA in IBD, it's off to an incredibly great start as you can see with close to 70% growth year over year and heavily penetrated in becoming the actually the fastest growing biologic across all indications, in particular, in IBD new patient starts. So we know the space very well.

    我們對這個領域非常熟悉,不論是乾癬或 IBD。從我們在 IBD 推出 TREMFYA 的上市表現就看得出來:如你所見,年增接近 70%,而且滲透率很高,實際上已成為所有適應症中成長最快的生物製劑,特別是在 IBD 的新病患起始用藥方面。所以我們非常了解這個領域。

  • With that said, I will say there's still significant unmet need in a large amount of patients that are untreated or not treated earlier in the course of their diseases. And we do see that to be a great opportunity for not only market expansion as we're seeing in psoriatic disease or psoriasis with ICOTYDE, but the profile of the product fits beautifully in that spot, I would say.

    話雖如此,我要說的是,仍有相當大的未被滿足需求:有大量病患尚未接受治療,或在疾病進程較早期未能及早治療。我們確實認為這是很好的機會,不僅能帶動市場擴張(如我們在乾癬性疾病或乾癬的 ICOTYDE 所看到的),而且我會說,產品的特性非常契合那個定位。

  • Obviously, the data will depend on how we look at it in the positioning once it becomes on the marketplace, but I will tell you we'll early access is one of the other keys and we'll see rapid uptake once we get the data results, John.

    當然,數據將取決於我們如何看待它,以及產品上市後的定位方式;但我可以告訴你,早期可近性(early access)也是另一個關鍵,一旦我們拿到數據結果,我們會看到快速的採用成長,John。

  • John Reed - Executive Vice President - Pharmaceuticals, R&D

    John Reed - Executive Vice President - Pharmaceuticals, R&D

  • Yeah, maybe just to build on that a little bit. I think the reason that we have had such a great start in psoriasis is because of that trifecta biologics-like efficacy, coupled with placebo-like safety, combined with the convenience of a once-a-day pill. And we think that will play very well across all indications, including IBD, whereas Tom referenced still a large percentage of patients are not on an advanced therapy.

    是的,我再補充一點。我認為我們在乾癬能有如此好的開局,是因為具備「三重優勢」:類生物製劑的療效、類安慰劑的安全性,再加上每日一次口服藥的便利性。我們認為這在所有適應症上都會很有競爭力,包括 IBD;正如 Tom 所提到的,仍有很大比例的病患尚未使用進階治療。

  • The data in our Phase 2 study were quite encouraging and look like ICOTYDE can deliver on par with the current monotherapies. Of course, we are very aware that some patients need something more, that they need a combination therapy, and that's why we are developing 4804, which pairs our guselkumab, our IL-23 inhibitor, with golimumab, our TNF inhibitor. And that is in Phase 3 studies now after really compelling Phase 2 data that show that in that refractory population that have failed two or more prior advanced therapies, this really delivers superior efficacy to the monotherapy.

    我們第二期(Phase 2)研究的數據相當令人鼓舞,看起來 ICOTYDE 的表現可與目前的單一療法相當。當然,我們也非常清楚有些病患需要更強的治療,也就是需要聯合治療;這也是為什麼我們正在開發 4804,將我們的 guselkumab(IL-23 抑制劑)與 golimumab(TNF 抑制劑)配對。在非常具說服力的第二期數據之後,該方案目前已進入第三期(Phase 3)研究;數據顯示在那個難治族群(先前兩種或以上進階治療失敗)中,這確實能提供優於單一療法的療效。

  • So we're actively pursuing that for those patients where a monotherapy is not enough and could see then that opportunity to migrate patients if needed beyond the monotherapies to the dual therapies with our co-antibody therapeutic 4804.

    因此,對於那些單一療法不足以滿足需求的病患,我們正積極推進該方案;若有需要,我們也看得到機會把病患從單一療法轉移到我們以共同抗體(co-antibody)治療 4804 所提供的雙重療法。

  • Operator

    Operator

  • Vamil Divan, Guggenheim Securities.

    Vamil Divan,Guggenheim Securities。

  • Vamil Divan - Equity Analyst

    Vamil Divan - Equity Analyst

  • Great. Thanks for taking the question. Maybe one just follow-up and then one actual question following up on the ICOTYDE. Appreciate the comments you've made so far.

    很好。謝謝讓我提問。也許先一個追問,然後再一個關於 ICOTYDE 的正式問題。感謝你們目前為止的說明。

  • Just curious if you would be willing to provide any commentary around the actual net sales in the quarter or on how compares to where consensus was? We're just getting some questions from investors on that specifically.

    只是好奇您是否願意就本季實際淨銷售額提供一些評論,或是談談與市場共識預期相比如何?我們特別在這點上收到一些投資人提問。

  • And then my other question is just around INLEXZO. So appreciate the comments there you made around the sales so far. I'm wondering if you can just quantify. I know you have the data coming up later this year as well, how you see the market opportunity for that expanding based on the current indication, and then what the SunRISe-5 data, what the size of that opportunity is relative to what you have currently? Thank you.

    另外一個問題是關於 INLEXZO。很感謝您剛才對目前銷售情況的評論。我想請您能否量化一下。我知道今年稍晚也會有數據出來;就目前適應症而言,您如何看待其市場機會的擴大?以及 SunRISe-5 的數據所對應的機會規模,相較於目前既有機會大概有多大?謝謝。

  • Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

    Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

  • Yeah. Obviously, we haven't disclosed any sales for ICOTYDE, but I'm confident we're going to be doing that next year just based on the momentum and the progress that we're seeing with the launch of ICOTYDE.

    是的。顯然,我們尚未披露 ICOTYDE 的任何銷售數字,但基於我們在 ICOTYDE 上市所看到的動能與進展,我有信心明年我們會開始披露。

  • Turning over to INLEXZO, also another exciting product that we have or even a platform as we think about TAR-210 as well and the opportunity that exists for us, we're off to an incredibly great start. Joe disclosed that we're nearly $200 million in net trade sales year to date.

    談到 INLEXZO,這也是我們另一個令人振奮的產品;甚至從 TAR-210 以及我們所擁有的機會來看,它更像是一個平台。我們的起步非常、非常好。Joe 已披露,截至目前為止,我們的淨貿易銷售額接近 2 億美元。

  • And quite honestly, we haven't reported quarterly sales, but I could say that Q3 was north of $90 million. So we're seeing great sequential growth this quarter. We saw new patient inserts grow 45% versus the previous quarter.

    坦白說,我們尚未按季度披露銷售額,但我可以說第三季超過 9,000 萬美元。因此本季我們看到很好的環比成長。新病人開始用藥的人數較前一季成長了 45%。

  • And I wanted to point out that this isn't a population in non-muscle invasive bladder cancer, high risk with carcinoma in situ. It represents roughly 4,000 patients in totality, so relatively small in nature, and we're still seeing one in three patients being put on INLEXZO in this patient population.

    我也想指出,這並不是一個很大的族群:屬於非肌層浸潤性膀胱癌、高風險且合併原位癌(carcinoma in situ, CIS)的病人。整體大約只有 4,000 名病人,因此規模相對小,但我們仍看到在這個病人族群中,每三位就有一位使用 INLEXZO。

  • You touched on SunRISe-5, which is a broader patient population, roughly 15,000 patients, and what we call SunRISe-3, which is the BCG naive population, roughly 50,000. This is where we absolutely see a greater opportunity for us to live into the number of $5 billion-plus for the platform. And I do believe we will do just that and above that given the unmet medical need, the simplicity of INLEXZO delivers and the high durable complete remission rates that we are delivering with INLEXZO as we look to expand in the population.

    您提到的 SunRISe-5 是更廣的病人族群,大約 15,000 名;以及我們所稱的 SunRISe-3,也就是 BCG 未治療(naive)族群,大約 50,000 名。我們確實認為,這正是我們有更大機會把這個平台推進到 50 億美元以上規模的地方。我也相信,考量未被滿足的醫療需求、INLEXZO 所帶來的使用便利性,以及我們在擴大適應症時所展現的高且持久的完全緩解率,我們不僅能達成,甚至可望超越。

  • Maybe I will turn it to John to touch on a little bit of the clinical development program.

    或許我把問題交給 John,請他稍微談一下臨床開發計畫。

  • John Reed - Executive Vice President - Pharmaceuticals, R&D

    John Reed - Executive Vice President - Pharmaceuticals, R&D

  • Indeed. As you know, the approval currently is for the CIS type of non-muscle invasive bladder cancer, which spreads laterally. The more common is the papillary, and in our so-called SunRISe-1 study, we had a cohort devoted to patients with papillary cancers where those lesions which project outward from the bladder wall are excised by the urologist and then INLEXZO is applied, and one tries to prevent recurrence. We showed nearly 75% of patients had no recurrence after one year and that over 95% had no progression of their disease. In other words, they did not progress to more invasive types of disease.

    沒錯。如您所知,目前核准的適應症是 CIS 類型的非肌層浸潤性膀胱癌,這類型會沿著表面側向擴散。更常見的是乳突狀(papillary)型;在我們所謂的 SunRISe-1 研究中,有一個隊列專門納入乳突狀癌症病人:這些從膀胱壁向外突出的病灶由泌尿科醫師切除後,再施用 INLEXZO,以期預防復發。我們顯示將近 75% 的病人在一年後沒有復發,且超過 95% 沒有疾病進展。換言之,他們沒有進展到更具侵襲性的疾病類型。

  • So based on that, the use of INLEXZO in that papillary form of the disease, which is by far the more common, is already in the NCCN guidelines, and the FDA has invited us to submit for expansion of our label into that population.

    因此基於這些結果,INLEXZO 用於乳突狀這種(遠比其他類型常見的)疾病形式,已經被納入 NCCN 指南;而 FDA 也邀請我們提交申請,把標籤適應症擴大到這個族群。

  • Joaquin Duato - Chairman of the Board, Chief Executive Officer

    Joaquin Duato - Chairman of the Board, Chief Executive Officer

  • Both ICOTYDE and INLEXZO are going to be, together with RYBREVANT, key drivers of our growth acceleration driving to double-digit growth. So they will become one of our largest products both of them.

    ICOTYDE 和 INLEXZO 會與 RYBREVANT 一起,成為我們加速成長、推動達到雙位數成長的關鍵驅動力。因此它們兩者都將成為我們最大的產品之一。

  • Operator

    Operator

  • Michael Yee, UBS Securities.

    UBS Securities 的 Michael Yee。

  • Michael Yee - Analyst

    Michael Yee - Analyst

  • Great. Thank you for the questions. Maybe two pipeline science questions. On ICOTYDE, obviously, you have great data in psoriasis, a little bit lower than biologics, but great data. In IBD, the UC data was quite strong, and just wondering if you think that would be replicated to biologic-like efficacy as an oral, and that differentiation there due to the release in the gut is a reason for the potentially stronger data in IBD, which could be a bigger driver.

    好的。謝謝讓我提問。我有兩個關於研發管線科學面的問題。關於 ICOTYDE,顯然你們在乾癬上有很好的數據,雖然略低於生物製劑,但仍是很好的數據。在 IBD 方面,潰瘍性結腸炎(UC)的數據相當強;我想請教你們是否認為,作為口服藥,它的療效能否複製到接近生物製劑等級?以及由於在腸道釋放所帶來的差異化,是否可能是 IBD 中數據更強的原因,而 IBD 也可能成為更大的驅動因素。

  • Second part question is on milvexian. I know you share in that partnership, but SSP data is coming up, and I just wanted to check in on your confidence that that should be similar to asundexian, and that should be a fairly de-risked indication as a Factor XI. Thank you.

    第二部分問題是關於 milvexian。我知道你們在該合作中有分成,但 SSP 的數據即將公布;我想確認一下你們的信心:它應該會與 asundexian 類似,而且作為第 XI 因子(Factor XI)機制,這應該是一個相對去風險(de-risked)的適應症。謝謝。

  • John Reed - Executive Vice President - Pharmaceuticals, R&D

    John Reed - Executive Vice President - Pharmaceuticals, R&D

  • John Reed here. Thanks for your questions. I'll start off, and then maybe Tom will want to supplement. But on ICOTYDE in IBD, we get that question all the time, asking might we see even greater efficacy with an oral because of the gut absorption. All I can say is to be determined. We were quite pleased with the Phase 2 data in ulcerative colitis.

    我是 John Reed。謝謝你的問題。我先回答,之後 Tom 也許會補充。關於 ICOTYDE 在 IBD,我們經常被問到:口服藥因為在腸道吸收,是否可能看到更高的療效。我只能說,還有待數據證實。我們對潰瘍性結腸炎第二期(Phase 2)的數據非常滿意。

  • I would also say the Phase 3 studies, as we saw with our psoriasis and psoriatic arthritis studies, are enrolling briskly. In the prior studies, they enrolled in about a third the time that it normally takes us to enroll in those indications, reflecting, I think, the real enthusiasm that both physicians and patients have for this oral option. So that theory about oral absorption and improved efficacy is to be determined by the data.

    我也想說,第三期(Phase 3)研究——就像我們在乾癬與乾癬性關節炎研究中看到的——招募進展很快。先前的研究招募時間大約只有我們在這些適應症通常所需時間的三分之一,我認為這反映出醫師與病人對這個口服選項的高度熱情。因此,關於口服吸收是否帶來更佳療效的假設,仍需由數據來決定。

  • Moving to milvexian, we remain confident in the studies underway, particularly with the secondary stroke, because of the asundexian data. As we know, in vitro, milvexian is a more potent inhibitor of Factor XI. We also have been able to have a safety margin that allows us to push that dose to ranges that we are confident are quite effective.

    談到 milvexian,我們對正在進行的研究仍然有信心,特別是次發性中風(secondary stroke),因為有 asundexian 的數據作為參考。我們知道在體外(in vitro)實驗中,milvexian 是更強效的第 XI 因子抑制劑。

  • So we remain confident in the results and expect that perhaps the secondary stroke data will be available even this year. It's event-driven, the study. The atrial fibrillation, the larger population, will be next year. It will be exciting for us if we can prevail in both those indications because about 25% of patients who are candidates for secondary stroke have atrial fibrillation. That's probably why they had the stroke in the first place. And so if we can benefit both of those populations, that will be exciting.

    因此我們對結果仍有信心,並預期次發性中風的數據甚至可能在今年就能取得。這是一項事件驅動(event-driven)的研究。而心房顫動(atrial fibrillation)這個更大族群的數據會在明年。如果我們能在這兩個適應症都取得成功,對我們會非常令人振奮,因為約有 25% 符合次發性中風治療條件的病人同時有心房顫動。這大概也是他們一開始會中風的原因。因此若能同時讓這兩個族群受益,將會很令人振奮。

  • We are confident in the atrial fibrillation study as well. There, we were able to push the dose four times higher, given our safety margin in the drug, and feel from monitoring of the anticoagulation status of the blood with laboratories, that we are in the right range to benefit patients and prevent thrombosis. So thank you for the question.

    我們對心房顫動研究也同樣有信心。在那項研究中,基於藥物的安全邊際,我們能把劑量提高到四倍;並且透過實驗室監測血液抗凝狀態,我們認為目前落在能讓病人受益並預防血栓形成的正確範圍。謝謝你的提問。

  • Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

    Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

  • Yeah, I just reinforced with John, I said there's an absolute need for highly effective oral anticoagulation therapy with the reduced bleeding risk. In AFib alone, approximately 40% of the patients eligible for oral anticoagulants are not receiving oral anticoagulants, typically due to the concerns on potential safety and the bleeding risk associated with the current ODACs.

    是的,我補充呼應 John:市場確實非常需要高效、且出血風險更低的口服抗凝治療。僅在心房顫動(AFib)領域,大約有 40% 符合口服抗凝劑治療資格的病人並未接受口服抗凝劑,通常是因為對潛在安全性以及目前口服直接抗凝劑(ODACs)相關出血風險的疑慮。

  • Operator

    Operator

  • Jayson Bedford, Raymond James.

    Raymond James 的 Jayson Bedford。

  • Jayson Bedford - Analyst

    Jayson Bedford - Analyst

  • Good morning. Thanks for taking the question. Just I wanted to go back to the international MedTech business. Is there any way to quantify the impact of the dynamics in the Middle East and VBP?

    早安。謝謝讓我提問。我想回到國際 MedTech 業務。是否有辦法量化中東地緣動態以及 VBP 所帶來的影響?

  • And then Tim, I want to ask about international surgery. First, just to confirm your view is that there's been no change to the underlying demand profile internationally? And then second, I think Joe mentioned taking actions internationally for surgery. What are those actions? Thanks.

    然後 Tim,我想請教一下國際外科業務。首先,想確認一下你的看法是:國際市場的基礎需求輪廓並沒有改變,對嗎?其次,我想 Joe 提到在國際外科方面正在採取一些行動。那些行動是什麼?謝謝。

  • Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech

    Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech

  • Thank you, Jason. Let me try to get to all of those. Let me start with the Middle East, and clearly, we've highlighted that as a new risk that has broadened over time. And really the effect is no longer limited to a handful of markets as we initially thought.

    謝謝你,Jason。我盡量把這些問題都回答到。我先從中東談起;很明顯,我們已經強調這是一項隨時間擴大的新風險。而且實際影響已不再像我們最初以為的那樣,只侷限於少數幾個市場。

  • We've seen increased disruption to ordering patterns, tender timing, and hospital spending decisions across a wider group of countries unfortunately. And we've also seen governments and healthcare systems become more cautious in their spending priorities with some funding and procurement decisions taking longer than what we normally would expect. That has created a more meaningful impact on purchasing behavior than we saw earlier in the year.

    不幸的是,我們看到在更廣泛的一組國家中,訂單模式、招標時點以及醫院支出決策都出現了更大的干擾。我們也看到政府與醫療體系在支出優先順序上變得更為謹慎,部分資金撥付與採購決策所需時間比我們通常預期的更長。這使得對採購行為的影響,比我們今年稍早看到的更為顯著。

  • That said, I think it's important, that we see this really as a short-term factor. I mean, the underlying issues have not changed. The clinical need remains intact, and we would have -- we would expect many of these opportunities to be deferred rather than permanently lost. I think that's an important factor as it relates to any form of conflict and certainly what we're seeing in the Middle East.

    話雖如此,我認為重要的是,我們把這視為一個短期因素。也就是說,根本性的問題並沒有改變。臨床需求依然存在,我們——我們預期其中許多機會是被延後,而不是永久流失。我認為這對任何形式的衝突都很重要,當然也包括我們在中東看到的情況。

  • On Surgery, as I mentioned, we were actually really excited about the performance of the business in the US. Our issue really was outside of the US, and as you know, primarily driven by factors we've discussed before such as the transformation program and volume based procurement and then of course the incremental pressure that we've just mentioned around the Middle East.

    關於外科,如我提到的,我們其實對美國業務的表現感到非常振奮。真正的問題是在美國以外;而如你所知,主要是由我們先前討論過的因素所驅動,例如轉型計畫與以量為基礎的採購(VBP),當然還有我們剛提到的中東帶來的額外壓力。

  • I will say that despite those headwinds, we'll focus on where we can have an impact and we have a lot of opportunities, you know wound closure growth continued to benefit. This is a category where we absolutely dominate, and that growth has been driven by innovation such as STRATAFIX and PLUS sutures Biosurgery and north of billion-dollar platform delivered solid growth driven by key brands like SURGIFLO, SURGICEL, and VISTASEAL. And we continue to see good traction with our endomechanical innovations such as Ethicon 4000 and DUALTO.

    我想說的是,儘管面臨這些逆風,我們會聚焦在我們能產生影響的地方,而且我們有很多機會;例如傷口縫合的成長持續受惠。這是一個我們絕對占主導地位的品類,而成長是由 STRATAFIX 與 PLUS 縫線等創新所帶動;Biosurgery 這個超過 10 億美元的平台也交出穩健成長,主要由 SURGIFLO、SURGICEL 與 VISTASEAL 等關鍵品牌驅動。我們也持續看到在內視鏡機械類創新方面的良好動能,例如 Ethicon 4000 與 DUALTO。

  • And so we are confident that we will see continued growth in the US, and to your question, we will see acceleration in EMEA and return to growth overall in the fourth quarter.

    因此,我們有信心美國將持續成長;而針對你的問題,我們將在 EMEA 看到加速,並在第四季整體回到成長。

  • I do think it is also worth mentioning our confidence in this business going forward. This was the core to how we started Johnson & Johnson MedTech, and we are absolutely committed to it for the long term. I would say the biggest reason for confidence is the fact that we will be entering the surgical robotic space. And combined with our leadership positions across wound closure, biosurgery, and advanced instrumentation, we believe that OTTAVA gives us an opportunity to participate more fully in one of the most attractive and under-penetrated areas of surgery.

    我也認為值得一提的是,我們對這項業務未來的信心。這是我們創立嬌生(Johnson & Johnson)MedTech 的核心起點,我們絕對會以長期角度投入並承諾。我會說,信心最大的原因是我們將進入外科手術機器人領域。再加上我們在傷口縫合、Biosurgery 與先進器械方面的領導地位,我們相信 OTTAVA 讓我們有機會更全面地參與外科領域中最具吸引力且滲透率仍偏低的板塊之一。

  • And so as we continue to execute our portfolio transformation, advance innovation across the existing business, and prepare for the launch of OTTAVA, we remain confident in the long-term trajectory of the surgery franchise. We do get a lot of questions on OTTAVA, and rest assured that when you come together for the meeting on December 8, we will provide perspective on the outlook for that innovation and further build your confidence in what we believe will be a material contributor to Johnson & Johnson's growth over the long term. Thank you.

    因此,隨著我們持續推進產品組合轉型、在既有業務上加速創新,並為 OTTAVA 的上市做準備,我們仍對外科事業群的長期走勢充滿信心。我們收到很多關於 OTTAVA 的問題;請放心,當大家在 12 月 8 日的會議上聚在一起時,我們會就這項創新的前景提供觀點,並進一步建立各位的信心——我們相信它將在長期成為嬌生成長的重要貢獻者。謝謝。

  • Operator

    Operator

  • Alexandria Hammond, Wolfe Research.

    Alexandria Hammond,Wolfe Research。

  • Alexandria Hammond - Equity Analyst

    Alexandria Hammond - Equity Analyst

  • Thanks for squeezing me in. So I guess as the CARTITUDE-5 and 6 trials have advanced in newly diagnosed multiple myeloma, how is J&J preparing to educate physicians and treatment centers for the potential shift to use it earlier into the treatment journey? And I guess how should investors think about potential to capture share from these existing frontline regimens? Thank you.

    謝謝讓我插隊提問。我想請問,隨著 CARTITUDE-5 與 6 試驗在新診斷多發性骨髓瘤的進展,嬌生如何準備教育醫師與治療中心,以因應可能更早在治療旅程中使用該療法的轉變?另外,投資人應如何看待從既有一線治療方案中取得市占的潛力?謝謝。

  • Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

    Tom Cavanaugh - Executive Vice President, Worldwide Chairman, Innovative Medicine

  • Hi, Alex. It's Tom. Thanks for the question. I think first and foremost, yes, we're anxiously awaiting for those trials to read out. I would say we're already doing that right now with CARTITUDE-4 across the globe. CARVYKTI is available in 20 markets, and we're seeing substantial share growth in the earlier line settings. And I would say roughly in the US, 50% of the utilization of CARVYKTI lies in lines two and three.

    嗨,Alex。我是 Tom。謝謝你的問題。我想首先,是的,我們非常期待那些試驗的讀出結果。我會說,我們其實現在就已經在全球透過 CARTITUDE-4 進行相關工作。CARVYKTI 已在 20 個市場上市,我們看到在較早線別治療情境中市占顯著成長。而我會說,在美國,CARVYKTI 的使用量大約有 50% 落在第二線與第三線。

  • So there's becoming more familiarity with the product and access to the product and excitement about it, predominantly due to the unmatched overall survival as early as line two of therapy that we see in versus standard of care. So we're already educating healthcare providers on the product and how they can utilize it earlier.

    因此,大家對產品的熟悉度、可近性以及對它的期待都在提升,主要是因為我們看到相較於標準治療,在第二線治療時就能展現無可匹敵的整體存活期(OS)表現。所以我們已經在教育醫療照護提供者,讓他們了解這個產品以及如何更早使用。

  • Some of the education that is centered around is appropriate patient selection, and the earlier the better, as well as proper bridging, getting the patients to the highest level MRD negativity to be effectively treated with CARVYKTI.

    部分教育重點在於合適的病人篩選——越早越好——以及適當的橋接治療,讓病人在接受 CARVYKTI 治療前達到最高程度的 MRD 陰性,以便有效治療。

  • John Reed - Executive Vice President - Pharmaceuticals, R&D

    John Reed - Executive Vice President - Pharmaceuticals, R&D

  • Great. Maybe just to remind on top of that, at the recent International Myeloma Society meeting, we showed five year follow-up data from the CARTITUDE-2 study that's in second line, showing that about half of those patients enjoyed complete remission out to five years with no further treatment. So one and done in five years of continued disease-free survival.. So very exciting data.

    很好。也許再補充提醒一下:在最近的國際骨髓瘤學會(International Myeloma Society)會議上,我們展示了 CARTITUDE-2 研究(第二線)的五年追蹤數據,顯示約有一半的病人可維持完全緩解長達五年,且不需要進一步治療。也就是一次治療、五年持續無病存活。所以是非常令人振奮的數據。

  • Ryan Koors - Vice President - Investor Relations

    Ryan Koors - Vice President - Investor Relations

  • Great. Thank you, John, and thank you, Alex for the question, and thanks to everyone for your questions and continued interest in our company. I will now turn the call over to Joaquin for some brief closing remarks.

    很好。謝謝你,John,也謝謝 Alex 的提問;也感謝各位的問題以及對我們公司的持續關注。接下來我把電話交給 Joaquin,請他做一些簡短的結語。

  • Joaquin Duato - Chairman of the Board, Chief Executive Officer

    Joaquin Duato - Chairman of the Board, Chief Executive Officer

  • Thank you for your questions and your engagements in today's call. As you can see, we continue to build momentum. Growth improves sequentially in the third quarter, and we expect further acceleration in 2027 with a clear path to double-digit growth by the end of the decade.

    謝謝各位今天在電話會議中的提問與互動。如各位所見,我們持續累積動能。第三季成長呈現逐季改善,我們預期 2027 年將進一步加速,並且在本十年末以前有清晰路徑達成兩位數成長。

  • In Innovative Medicine, growth will come from both our existing portfolio, including DARZALEX and TREMFYA, and newer products such as ICOTYDE, RYBREVANT, and INLEXZO, as they begin to contribute more meaningfully. We see similar opportunities in MedTech, the potential from our Cardiovascular launches, including next-generation PFA and IVL catheters. Additional data supporting Impella. And OTTAVA in robotic surgery are not yet fully reflected in our growth.

    在創新醫藥(Innovative Medicine)方面,成長將同時來自既有產品組合(包括 DARZALEX 與 TREMFYA),以及 ICOTYDE、RYBREVANT 與 INLEXZO 等較新產品,因為它們開始做出更具實質性的貢獻。我們在 MedTech 也看到類似機會,包括心血管產品上市所帶來的潛力,涵蓋下一代 PFA 與 IVL 導管。支持 Impella 的更多數據。以及機器人手術領域的 OTTAVA,這些尚未完全反映在我們的成長之中。

  • Taken together, these drivers position Johnson & Johnson as one of the cleanest growth stories in healthcare. We will provide more details about our portfolio and later-stage pipeline at our Enterprise Business Review later in December.

    綜合而言,這些驅動因素使嬌生在醫療保健領域成為最清晰的成長故事之一。我們將在 12 月稍晚的企業業務回顧(Enterprise Business Review)中,提供更多關於我們產品組合與後期研發管線的細節。

  • Thank you very much, and enjoy the rest of your day.

    非常感謝各位,祝各位今天剩下的時間愉快。

  • Operator

    Operator

  • Thank you. This concludes today's Johnson & Johnson's third quarter 2026 earnings conference call. You may now disconnect.

    謝謝。今天嬌生 2026 年第三季財報電話會議到此結束。各位現在可以掛線。